var title_f18_1_18448="Urine sediment showing a transitional epithelial cell";
var content_f18_1_18448=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F83886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F83886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Urine sediment showing a transitional epithelial cell",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 503px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH3AfQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1a6hK5K9Kis1O/aRx3960Hw4AxQsOyTK15jZ9Ap2RJGFXAQYX0qdcVGg556mn4wetKOpkx5xjA60AYHPemE7WFPDB8ZGaoRKqfJ1pVbYQvXNJ7DpTio4b0oJJQMjNNZATQDv4HFGDu+9xQgHL8tIRmlGDnjpSc59qYDGBB4p4Py9OaQ8HilySKRQhH8VB52mjtjtR6UAB+9+FHejrig5yBQAueDRFznNGAMimpwTQMJk3EY7U5ThaXJpD6GgBQcmkTlzTkApi5EhI6UCHkc07Hyn6U3dzzTg2BnrQAiZ281U1CW4it1a2i81zIAV9qtyMqMu5sFugoyc0AIXCsARh2GSnpS5oPNJimA4GikWloATp1pSwPSkb3pEABOBQAxiafFjHvQwHpUY4fH60AWOO9GAKAuBydx9aRuRQAuQaDjFM6cUooAKKKQ07gIRnIqGBdqtuFS5waRuRgdKVxoAOKaVxzmgZoxmgA4HNIcAZ60uARikbgZHSgRGsIDF35B7U8AHheKd1XI600gLtJPJoARhhSKhWT5ttTOME+hquigS9KALAxio3xnio0EouJC75i/hHpSsMj370XGITTGx+NIxx1poJzTuNCqMt831qAsWlZe1TtyBTCADmi5RAoIbb2ofGPpTmwp96iPJOe9MoaQDTT8pyvHrSnINBHO4HmmgGq+0Yjl4oppBzxiiqG6aNBSAgHepATiohUiniuYwHAHNIevWnA54pCwHA60LQB3IHqakiJA+ZcVEnHWpQc07gSoRjrTv5VED6U4HIINFySVSG+7SGLL53UkfFPzVJgOzg0MPlyOlNIyDz0oDfJjrTACOlKAcUUucUh3GmjBp3WkORSYJidKQkls0nOacKVxgxy3FOPam96XtRcYU1stx29aWlFNMGIuVGBzmnkcDHWkHWnUxDJASBtGTStwqg8GlyQaa2WYGgBJYVldWc8r0p4z359KWjNABS5FJmjFAC5FFNIxThQAuAaQDBpVpD1oAaxA600kMhVjgnoaVvm4qvMSJkHagaRZjUxx7c596crA96RmG3j0qK3YMSad0FiY9aQmjNIRxmiwgzR2ptOHSkMYaBnvS96KADigkfjQRmmnYoy7YxzVJXAUUxzkYojkV2+RgaVh1oatuJeYvG3g5NRSIWK88ipFHBoP3fepAaR8+KY4w9Pf7ue9MGCPm60AM28qufl9aRcjOR9KceKbuzQNDXUHrUPQmpz1phANBWwwnimmnsABTGoFcr3G4EEDihhlQRUj8cnkUzryOlO5auRsDimEccnBqZqjcZNNMbRCV560U9xzRVXFzsurTxSKR60p4asDId1FKDg4oTkgUMOeKAHYpQCAcUwE56U8MV5I6UAOTjhutS5GPeolIfLKQfpThz0oJHhjiiGXzogwBRvelTjrxR94kFcemKdwHkArjP5U6Dg4bpTIxxzT80XAcSN2KaTyRTC2G5oDYYnBIxVATJytMBYk5xikU5Xk4pynAxSY0I/TjrTS2Bx1oIOcjmmuABmpGCuSeetSE4Umq4YZqYHI56UDIraYy7skZBqwCDVOGExXBK8qatDlyB2poBzHHShWJ60180IeaoRITSZoNJQAuTS5/Om09RkUAJg9qdmjOKTIoAXr1opAaWgBRTSeTmgHj2pq8nPb1oAUAA1T1FmSLcmC+eKu4qvcL8wyMigaK0ck21RJg5HOBViDEXXgN0zSshZgQMdqc0YYgPxipa1KH5xxmgvkYoI78gUmO9UpdCRwpTwKQcU2Vht4IpXGGc04c1HGfl5qQGmIDwTiua8SXkovbaxtMiec4yeQB/k10xOfu8n1rjfE1wdO16z1CRd8MJ2vj+7kZ/lVRH6FvSZLiy1k6feEFtuVYDrXSKQVAJy3fFcTZax/wkHi9bm0RktkXAZhjPSuxEyvKEUrv9BVv+8S03uTEY6Uzvmn+3eonOBWbS6BYVj8wNRyDJzTQ2T1qTqKQEbjiowMHipWpqjk5oGiNzimA5b2ply2M4p0ZwmW44oKHOPSo+3NPLjaSDTByDk0CGcOD7UwlQCe1LMNsRxxxXO3usJBHIiyKzKeQD0q4q5vSpORvB0Y4zzSPgHB+9XDrr0iOZGJAzxnvW7oGrS6qLgS28kRiI2SMMB/pVulyq4TpuO5quxLfdIopzSMCMANx1FFRcwLgI6d6cAe9IPpT16VziFUY5FPIxz3oXqKMkqeKAFGMjFKRnA9aZEu3r1PNSECmISJQgYCnrwARTFOAec5p6N27UiSQYYc0Rk96j3FW46VIDkU0A/I7UuahXhjSg/NimAsnNIX+UCnPjHFQSAjmiY0TKcipR0qCEk9ambgcUkULyelRvx1pxY4odenemIr4BYkd6mU01lwRij7pFSMlIAGRUSMwmbPepB6g5oJydwFNAIzZyPSkU0Bckk96QjB4pgSg8UZqMMc4p2aAHCnBsU3gCk5JzQA/rSUA+tFAhy0tNBxThVICHzQ8zQiRd6c4p5O5wenHSoxbxrcPMqASP1NS45z7YpgP7UyRc4NPFAPymgBgYYye1Rlt4yvamy5KECi0+SNgefrUNjDezKM08H5aTt2phYZ460rjJCeKYo3NjtQT8tEZNIQSHaMCnxHIqObgZ6mkgZm6gCmh2uPdysgA6Vla3aRXVviUBgWxV24fkIBz61BKFKFN3TnJqpGlN2ZnaXa2+nnEMYBPpWtCmJxNjHasfcROAT+VbNq5KhT06800zSurlxvXuaik+7TyfmpkhGD6VTZyorKfnNTg8VWySWI6CnhiV4HNIqRJmkZsUwnBpQ2B0oEMfa3UVFvCqdwqZ2HbFRNhhggUDRFGd7HHSnHinKNowOhpkvUYouUcx421o6baJBG37yZuD6CucEMYtw/mb5HGW+tQfFWXGoWwOcJjGO9UdInZ4VYgYbrXTTgnTuephY2aQagDsAXsa6/wTKZIChPQVzt9EWiJVTmuh8CwmK2kJzu96qMrxaHjYpbHUEAGikcENRWFkeQW1qRelNWnjpXMK47tS5wwHrTR1qQUANyS3TpTiaXvSO1OwhmacoyM+lMpyHBpEkrHCZp69KiY1IvSqQmxR96kH+spVOCaCM0wuPJB6U10OAaUmn54FJ6gmIoAFLnPWjGBmmUIrmuL3pw5WmGlU0BcByBmoJ2KuKsZ5qJ13HnpRYdwibA+tO3YOKNyquKj3ZNLYEyUtzSck0m7ikye3Si47j2+/+FK3SmggjilNFwuKjZFOU4zTBS5p3AfjNLSA0UCA04GmninKadwBmpQcimUo607gSCkJwQPWkPSonk24c9RxRcBZOGpoHpUE1wpkAHpmpI3DLnPFS1cdnYGBHfikXG6nqwfgLkVTa4IvFt1XG7PNKw1qWgcnA5pyEBiO1R5EI9zSbQ4UK2C1FgY+4HBNNVgqjnmiVGDHLZOMUwhY13HrTSFuF0rOqlOOeTVDUwFTK5DAc1aS4EoZScVVv4ZJEDI/yDg03qbU9CnbFGAIOWrWsy2fmH0rHsbFxKcNwa37dNiYBzihIqvO2hITzUEz8banYqRz1qlOSzVRzR7jWYh1A5Hep92cBRTI4+KlUAUFPUjandR16VHMWSOUxjdjpSoBsVs/MwyRQK4hHNJinGlbpSGmM9aibkEnipMZzimTLmMiiw7nn3xGtEnaCQjPI5xWbZWmyNQhAGK7LxJY/atOCqOV5rkP3kSLHtO4EY4rSjPTlPXw8k4mlBDJIUQjrXTaRbfZ7UjGCap6HGFVXnHJHFbpwqAVctNjmxNW+hSn8zzDg8UVIx5oqDgNJeelOHTkUi9PlpVzjmsCR49aevSmdqkXpSYBUUrYYAmp1Hyk1XlTewI7c0wHY5p23GOaReaU9CaRIoG5sdqeGxTU6ZpaaExy85NSKBtz3qJTzing/NimIUjNPX0ptKOKAHY560wnk0uaMUDQ3rx0oHXFKeBRjjNAxdpHNNyCwFKMYznmgEg9OKAEkXb2zUbKcbgPwqUNuzSHJ6dKGNDEBPJHFOPtRtOMUdKQxN2D0xQXpshyM0xcupA6nikBOMgZxxThyaYqusYVutOBwAtNAPAI6kAUZqGVFlAG8ginZpgPJzThUYNOBoAdSjrSUhBP3aAHkj1qhqUgQDB5x0q4OPvVhao5W4l3HgDIq4q5dJczK0NwAjO55JwBUlhe4n8uY7Q3T3rHuWPl7weMcVFCWkCOT8ymteXQ9F0FyXO5RiqEDt3qKXy4x5j9f73pTdPkMtmGbripZIBNFtbpkVzvc82WjsVpGfAcDcpPerCIGeKRSRjtUojUDywOBSRJjPoKYMUj5z39Kik+6WYfhRcSFcY6mojJubYaQRGSRJJgoME+lMTK2joRk7sD3qzAyJKI/wCLrUpRfMYHr1phzWKttDhgzfLjtU1xJsH7sZyeRUpPymqwYF9vc81Qn7xMmdwDjqKCopVHzZbtSmgm1hgXGeaQ0pOKYxoC4EgAheAetNOO1Ic0g70DEJo69TikNLjd0oGhoBUkjntTgMg5pR6GkLYoGV5Yhz3yMYqiun27SAsgyM1qsON3rUBGG3CpSsaxqOJnzxBQABgDpUkL71GTU9yoZfeq0SbFFaIJO+pIw54op26imZF1TmnjiolGfang7eOtYEkop4NRA5FPHFICQmmGgN7UZzQA2lFIeDTgKCRwpV6U3NKDimgFXvTqavc07qM0wJQOKMVGHzTxQSPFIetAOKKACigDJo7UAJilC5NKDx0ozg9KBoaFwaJDzTJGKkUp5xz1oLHKMikbpinEbVx60AjGCKAICmOKEXaalbp0pFGBzzmgBaAuTn0pSPelWgAdc01ic08detOIFADBjHNHPanNj0pvPY0AOpR1pKVetMGJJXH62zpcNs+4W5rsJOlYmoxBwwKY/rWkXY3oPlZysxLAbPujk1Ja8IHPy89PWpWjbLKqEYpUgeeNSoJZG5UVo5aHpSqJwOssbiIRoMYYjpVxh8vsazYLfzQkm3YccitEgkDngVh1PIqasey8ClK9Kb1Ap2D17CnclFa8GOapW8gkn+90q25E7Fc4qjbWTRzsTkgmg0TsjQjixKSDmpcZNIoCcCnIp3daDGWpXMyEkR/fHWlXGN38VUVUrLK20qSeCT1q3D8xGOo4PvQacvukrZADN3pDUpGB83zVE3FBnawwjJoI20qHk8UkxyOBQBHSMeg9adik70FCFR070q/LUZz5m7PHpUjmkxoRhmmHiiaXy4twXd7ZpGBIXjG4VIxc0hbAp2AFGaa2NtNDRA+M5qJvmJNOlJDZ7U0NuHTFWWJmimN1ooMy+OKcnLUiinisSRxGCKWgdqeKAuIBxmmk4NSAZNI60CuNAzRmm0ooELmpcVFjNOUFDTQrj8cGlA+SlHSimFwQVLjimtQB0p2ELRTu1IBzRYAHWhvmORTscUmKLAJnaN3rQeRupcUEcUDRXuGzgCnwDjBpphLtn0qaMbRn8KCrinn8KbT87VYryaVFDLluDTsFxq4PFAwcilzg7vwqN22nI70guOAxQfm6Um3PNJ3pDuO2mlGRSAUr8mgB2Q1GKM4FIRmnYVwozil4+6KBkHFOwXEbkVVuot7ZI4xVulbkUxqVjnDbEyEqOM1d0izECySMMsxq+U56Cp04WjoW6zasGxVXgVEOhqR+RTVGDikkZXuIKbK527RUxGOap3d3DFjzGAajlZUU7hCgQ7jVrnGQODUCbXi8xjgdqmTDJuQ5oQ2Iy4NMJxUrZxzUfQGmQylqqSyGMRDoMmn2iMsQLdTVsHcKYy80D5tLC9aY5FOFI4+SgkiB5pW5FCihxQMa1MNOIpvY0DuMNKoJoUYan0mNMYB1B9KQ7vLDY4BxT25oPIxUjuMkBPNRkYWphwDjrTcZU+tMaZVkGajC4qYLyaTGKpMrmIGHNFPfk0VViLl5RSmmqDTwOKxECnkCpUUk0xB8wpFaQSED7tITJOc0xzzTz1pJFyKBEbHacdaMZGaagI4apWXC0AOUYGacCD1qLdhaevSmhMfnFOHNNx0qRRTEJingZwBQRimq3NWA4kA4p2cGkAyN1C880ASH0pMUnUZowaADvihh2o6GmbvnxUlDgCOlO4xjFJRQgGqCA2Tz2pe3zUtBqgE6n2pCoyM9KB1pW7VLAQ+1BApaMUhoAcUCjFIKBi7Se9OA+lJj0pcGqQmKyjHy9ajQtuO6pCcUmMc0xCU49KbQTmgBpwTTx0poXJpyrQADjrSH72aU9aToCT2GaAsZOsamIFKLnd7Vj2ri9uIhMxLMeB6VneIbn/TmdTxnFV9LlkN4p5BXnNawaaPVhh7UuY7uVlSER/gMVFpbOpkjdhnqK5+51Ro4mYksw6GnWWovJexSAna3BocUc0sO7XOvwSoyRTNtPzwCPSmk1k9Dj2Y0/KKQHjmnEZXNRp3oAUihuVxS0jUAMHFIxpTTGoAB81NxyaF+bpTm4FAEbEDtQDmlK5pBSY0O6daaoy1OwCOaDleRUjI2+Vmx1pAcA560E5JJ60hoGM4BqNxnpUjUw00NEGKKcetFbIkuDLDA4xT4wWX3pueflp2doyKwAVhtHWljbimbtw560DINJgS0cmlHSlznOKAGbccmkY9qXJ701qRIlSopNR4p+T/CeKaAdg5qRDTR90E96WmA8nNIAM9KKUdaskcxwwA6UE46UEEtmhgKAJEPFIxoXGKDzQAgOTijZ81OQAnHelX5icEYHWgBkhKrwMmmwksuW61Nn2oxzmgaGdxQ3NOYZHFIBQMFAx05phGWp5ooAaVINLTwOOaaR6UANopcUYNABRz60oFOK4oAjxSr706jGKAGGilIoUEjNACHpxThnHWgqcgfjThQAwdeaVh8jfSlxg0rcg4pMFuef63Z7Lti33SelVoh5bAA8nvXYarYfaVLADIrmHtXS4K7TgVcHY9ajXXLYpojTyvF0FO0xZ3eKGEZKvya2I9NkkQtCAGbqTxW5oulRWSbxzIetU2TVxKSsX4wVhUN97FNA5qR8Z4NIBgZNSeW9XcD0xUajGaeTz3pHIyKkBKYM981IBQR6UAMNMIzStSjpmgBqgY4GPpTGUjPNSdBUZJ5zQAxc7etFOXgUBSaTGhKM0n8WO9O2mpGMHU0jDPSnYwaQnniqGQb95wB0prmpFQKTio5BtBBoGV2JyaKDyaK1RJfWngevSox1qQHjHasLgIR8wxS96dgYOKao5pbhceTxQpocYUUKBgUWFcU0gzSHl8ZpQwOQvGOtFhBtB6mmAnbSs1Ko+XB600BKn3BmlpFBCingUCuLSrSU5asQ8UdTTCT2oD0CY8cHFFC9cmn4B6UBHUEHBNKsYUZz17U4AbcEU0gZHtQMb3p1GBRQCA0lOA5pcD0oHcZijFP2+lNIIoGOA4ppHNKpNDUAJikpaVRQAg605ulN78Uc+tADnA7Um096SnAk9TRYBrjimAkcYqY80nGc96AGEswz6UHpT+2AcUmADxzQA2lFBpDQADjIIqJ7WFzuKjJqYEmihoItoYkaJwAKU89OKcfWmk59qAbbepDKMHApGJAFSbMt6im4HIIoAhjlLSYxUpO7t0pEQLyBz60ZOaADOKcOlNb2pATQA1hkGk2nZUm2jIAwaAGEUxhT8mmucdaAG4oBPpRnPSl68UmNDCgB3U49KXYe/SmmlYYmOKY44p/amMTVFCZGPeoXHJJp560xiWJHpSAruPmOKKkOM8CitEKxY6Gnjk8UgIYZFAzjjrXOIkAI60qjnNNTOOalHSqQmNk+bhaMEDmgetL1oER7cHOeaailC2O5yalNNFADSpPWlO7fx0p1OxQJjg2aeKYBinrQIXNLg0mMUhY5GKsCTGOtOCjrSjkjNQX06WcTSMeKaBR5tCcEfhSlgKwLXxBDI2M963YJUuUDR8inYqVKcNx4JNO7UdDRSJEzThSYpyjmgA4BozSsORSYoACT2phye1PooKGilNLijFADcU5RxRihelIBAOTRil7mimAYpOlLRjNAB1pmckin9KauMmgA2k9aXke9A+9S0gGHrSY4px60lAAFIopc4HNJnIzTAM4prc0Gg9KQDV4+lAAySaBS0ANOCDio8cH1qdAM1Gw5NMBi+9KBilUUznftpAOY9Md6TjODQv38HtS8b6AIyCKay561I1MNADMc4FL0oIxzSnpQNCKxzg0ppvendqBkZIzTGHFSHGKjKljjtQMjNMbKkY71KRsqF2y2fSkAx8BsHrRTmXcc+tFaIYWEvmIO4q0uck+9YXh273wx+hFbxPPFYrcqtHlY7IPWniowPzpVPOKZkx5x0oGBTSaOfSkIU4pvFBNItBItPBz06U2kB29KAJeKXOKapHrS0APzmlABNIKenWrAcD61xvjvUmgVYskKf1rsSOM9q81+J0/mFMLjZxmtKa1OnCK9RXMSC5MRBUkKea9K8F3gntMZyRXkFvcloNrDtkV3vw1u+qOcHPANVPQ9bGUk6bPQqXpQepox6VkfPoUGlzg0gFK3TjrQMd15pKVPunNJQAGjFKATQOTQAlFPxSN1oASkIweKdg4zjikbrSACBikxTiOBSfWmAmKPpRSmgBhGaTbjpTqKChOaOadRSAYSMe9Jk089DTDQAh560KOMLS0q8AeppgN27jgdaXA6EZp2BnCnnvVe8uo7OEtI4B7Z70WC1yRtoBydijvVSXUbOPIMoJHU1z99c3OoITkxx5wB61CltEiKpyW9TVJHTDD3V7nTQ39vJyko5qy2CAyHIrjzbRsxA3Kw6HNTWd3d6fN+9bzYifyp2E8O7XR1Iwoz19qYchs96W3nS6jEkJGe4pxGelS0c+t7Mj6nJ60mOc96cevFJikA0mk470uKa5GOaQAcHrTWz26VGjlmwakBznPQd6BoBgj3oJ4oUgnIOaRiPWgY3FBFKORxSMeKAIz1qKUDPA61O3SoZOgoGhhJHGaKQ9aKZJy3haVjHGp9K7GM5WuR0CExbPWuuiGFFQtzpxDTehIOacDtB4zSLxUigYyetI5Ssjl3JxgVK2e1LjPalyADQAw0i96CaRTzg0EkgpMUoPzYopgKoxTxTccU4UWAkpR94UgIp64qgIrsN5ShTyTXCfEu1zbR4HI6mu9dBIVBJ4ORiud8cWT3untgcgdq0p6M3w0uWomeRQptKA9O9dv4L2x3qsmdhrk7K3kEjwyL82CBxXpXgzSfKsVklU7s5FVN3PaxNRezZ2SncAR3pR1oUDaMUp4HvWR88LQetICacADQAUU4gbTihRkUAJu2ilXuaaV3HFSAYGO1ACUhzn/AGe9LQVyM/pQAwY3YVuPenYzUF1C0yqIztIPOKsLQAg60P1pcAGkJyaAEII5NUdR1jTNLnsINU1C2tJr+XyLRJn2maTGdq/49MkDqQDdLZOK5X4meAtK+IHh86fqY8m6iy1neouXt3P81PGV7+xANVCzfvET5kvd3OsYYODwRSV438M/HuqaJrw+H/xMPk65DhNP1F2zHfJ0QFz1Jx8rfxfdOGHPspBU8jkUTg4MVOopoTFFLmkNSaDSKbTicU3FIaEp2MKGoAyaU9CBQhkc0qxoXPFc7cM13cl5eIh2q/qknnTCEH5B97FZ91OrYRB92rSub04dx0yoowvSonQYBpRtMKs5Oc4xmmsQMhjxjjFWjqjEgk4fIp/fLjIxTZPmAK025n8tVIxwOeKdjTleyJbGeS1uN2f3Z7V0kMqyJlTXLbzPCCMY9q0dIuPL/dyH5O1TKJx1qbvobLY4IobpURlTOAaezfJkVFjnasAHFRSLT1kHQkZpT3zSsIrInzVLgBCKQ/Kc0MS33P1pDWgkYAFDKDTgBt5+9RigdxgGOKY33qk701gOtAEbVC/3jU8oCrnNQZDLuHegaGUUZHeimQULG0IfPSteMEKM0wJsxtqUccVmXOdxwp2TTQKdQSxQe1BXIoXrQ7YoEREHHSkHDDNPzRwaCRFzu6U/qeKQAjpTkqkA7sKUUnrRTAeBTgKSOgnHSgBQcGiZBPCykZBoHPWpEOVIWqiF7anJt4che/3rgGuotoRbWqxqOgoSMB896nONuKGzSVaUlZhCSVGaV87qRFPbpSkEHJpGYoNOzzUdOUj0oAkzlTzSrwKaCMdKKAHAnNPJpi9KWgBaToc0tBFADQDuyDilAoxS0ABppHFONIaAGogznvTzSKTSk5oA5H4m+A9K+IHh86fqY8m6iy1neouXt3P81PGV7+xANcN8M/HuqaJrw8AfExvJ1uLCafqLtmO+TogLnqTj5W/i+6cMOfZs1yHxL8B6V8QNBOn6mPJuostZ3qLl7dz/ADU8ZXv7EA1rCatyy2MJ02nzw3OtIIJBGCKSvG/hn491TRNeHgD4mHydchwmn6i7Zjvk6IC56k4+Vv4vunDDn2UggkEYIqJwcGXTqKaBhxTT0pTSVJoAplw6xws+RnFPxWZrEpHlxL1J5oLgrsy7iR0R5CDvft3qC2ZG3FsbqnuzmTDemBUCRhUZquOx6EIlO+maEgg5UngVWivW8w+aCFbgZ7U26kaRlAGQGPNZ99IFjLE8g1Z3Qppo6MkJGOfmPQetVZlMkfIPWorG9W7iVG4dV4q/btlQGGR3NUY8vKxiMIrYKhDN3A603zTtG08rTJYt96AjbRVpoEWU46GkzOaTLNtMzoGJ+taMk22DJNZVmR5rRirMr+YhjHas2ck4ohsbtpp8ds1uHkcdKzLKzEJzitEnAAFSzGo09hjnPFKo44oPPWkAPrUkdB7cL702lYEDmjtQIY3B54z0pGGRikJKMd/IPSk3EdepoKGMpH3jxULE7iACF7VYPzdajYckUmNEBXmigk5oqiGSoxHvTgSTmoxUinFZlWJFJx0FPHNR7uKVTQJknSo5TzTieailNAhwOacBjoahQ1MDkUCY8NjtSgAUylzVIkfSimA08Uxig4p27mmUtADj0pwPGOlRA5qQUAPQdqft9zTAaXdQA7OOlL1Gc1GTT16UxDgM08DFNWnUAKD7UUDrS9KBirS0iniloAcKDSClNAgopKKACjiig9aBhkUcUlKMUARvQlI55pUx2oA5T4m+A9K8f6CdP1MeTdRZazvUXL27n+anjK9/YgGuG+Gfj3VNE14eAPiYfJ1yHCafqLtmO+TogLnqTj5W/i+6cMOfZWNcj8TPAmlePvDsllquIJrcNJa34A3WrdyT3Q4+ZSeevBAI1hO/uS2MKkGnzx3OwEbNuwOVGTUdfHmu/GLxTpdlpvh27u7S+vdC1NJzqlrciVb2OL7iMw4cHJy3UjAIyDn650rULbVtMs9RsX32l5ClxC3+wyhhn35596KlPkVx06vtHYudjWDeM0l1I6gHbgAVuOdqE+1YHmeWZXPIas0dtFXZUuGAKqT71AsgMb7fSqsheSdJ8nYG5FW1VRA7eorRaHoxjrqZFu/myuo6gmql7Cko2ZOc5NSgSQvIyA8800sjxlj98ckUHdDyIVYRurD5NvHHet+F/NhQpxxziudkkWSIgDpWvos2VEePerWxFaOly6EbzskADHWnSuflH60y7ZsfKaZESwJakcTH2zst6CoznjmtW1t5BLIzDjrVKCMHY4GDmuijUqOe4qWctWSRFs96cBimiTdNjBqXox+lZHKRSDA4pVXjJJoZsmng5AoAaw460xzgU9h3pCOKAI16ZPOf0pM9iKkxxTG4FIoYQfwqKTHrUjScYqvLkN1pDW4Yz6UVGHwKK0SG1qSdSKe3XNNj605gTwBx61iSOTnrTTuEnH3afGNvvTwc0CY/gqMVE4p/QUwjnrQIYBS8gjFPCijOD0zTsJi4yOadSFuOlANNEjqchzwaaoz3xTsgCmMc49Kb25oGM/MeaUt2Ix70CFFKARSKCelSA8YxzQA1MlyPalc4QZqJnwx5xxQsqtGMmgqzLC84PrUueKjQggY6UvfFOxI8GpAeKiUe9PGaLAP3YpM7utNGc9KdQMUDFOFN96cvNADxQaQGjOaBC0jdaKDzQA4dKQ9aUdKaaAEJpOTS8+lJ0oGIy8cUxcjtUo+tNxnNADCaqavp1lrOlzabq9nBe2E334J0DKT2PsR2I5HarjDHShOQTQm1sJpPRngnjT9nDQ7/AHz+Fb+bSbg5ItrnM0BPYBvvqPc7/pXcfA7Q/EnhnwfLoHie2RTps5FpcxSiSOaCTLYBHPyvv+8AcMvFehE/MPlyPU9qd1BJPT2rX2jkrMzVGMZc0SC9k2WrZ4yMVj3QCIiL0cc0zxFfYngiQ/ITyafO6OV2nPFQkd9KLWplrHgiP+AGrLKpXB6ClwAxjHJP8VOYjbtxgirOvmfQpSwgEydsYrC1GPymaSMZ9a3rgOUxjA9KpTwBozk846UHTRn3MhArxjbwW61f0ZWWZ1JzxxWbDDcLclHTAPSt+yh+zg8ZYirRvWkrWJ5IxtG7rioImCRqrHkUSyFP9YeO1QWY8wszHNI5LJo2IJN4U+lb0ZzGh9qwrVA0QAOOa3IB+5UZ6VLZ59dakbHbJxUrDvUbjad3WjeWXOMVkc45sHim00DjOaeo9aAEzikJzQ46elIBgUALnbUUpyKcxyD2qJHBJBpFWGNmoXHJ3dKtEZqB/vsD0pDW5XI546UU/A7GitUN7ko4p6uAMVXlJGMVNEdwBrAkkHNOWkNKKBMeelMNP9u1Vpi6uBH0J5piLC9Kb/FTOp205RnPtVEkhHFAFR5xTsbuaAJccU0rSKTyBTwAetABgFgTUbl0lDYyp4qXOeKhuj5cJYetAiwWGRk4oJ25NNUgpjbg8HNJP8oJ9aBoo3e+QnyzzT7df3AB+9SxLhGz3NPQ44qHKxrbQuW+Qig9hU2KhhbEar6CpgatMyY4U4HFVEmxLt9atDgU7gOzzS0zNKtADh1xUnSmDrThQA6gUlHY0CFopFobrQA4Uho9KSgBcijOaSgnFAxjHFKlMYkHNOQ8UgFbrSM204oJ5pKYCc5J7Vnare+Uohj++9aDvsjZvQZrlby4YymZurHFNbm1KHMwvkjMGJDmQGqwnkhTAGSBVK+ZvNCDoaZIdiDPWtlE9SFJNWL63jrhnHJ71cjkVlDHrWND+9janeY8QCUONhuFjVnJYH6Vmhm89c/dB5rQR9ycj+GoAEjwxXvSsKOgOFdicDd/DUauzkj+JeDTgu6UupwPSpEdNxwORVCldblW4O/Ct1qext/LZlNOYF246UsRAJHpSYOV0aFgmHxWzjaoFZem7S+T1PStJQTuz0rNnnVnqDjKVGOFp7UwjNQYgPuU77wGKiY4pyvSYDm6YpSOKRmyKbmgCGQfeqBM5q6eRURXFBYgOFqvN83I71O1QysOnekNbkQXAxRQAaK0QPckIDDFPiXAqJTjrUgbvWJJKeoFOApi8jPpTs0CY+mMT2pw6U1qBDf4fekDU1mxxQtO4rDw3qKdnPSo6lApoGKM9jipFxjkZpmMU8UxC8VHcr5kDqOvanZozQIrWz3TzfvVxGBirjrvXb0xTcEHdvyPSnxvkmgaKk6mPB7CgsMKcVPdDKH61A4AjWspI1T7lmMHAOan529KZb7So9aa8pEwTsa0Wxm9yJiBMMnBq/1A+lZ9xCzzIy9K0B0H0piCnCm05aYDs4NPBpuOKTPNAD91Gciko3YoAUcUE5pN1JQIeDmikWnUDG5oz7UlJQAOA3tSAY70tJQAnQ5pRyM0YyQPem9Gc9hQgWrMnXLsp5dtGcSSHOfQVi6ojSRqinDL+tXLpTdXs03dRtQVQMxjKiT/AFmCDWsIrc9CjBRVyhcghEDMN/riql3NkIuee9aV75bCNj1rnHugdb8nGQK1uehSVzaikVVUKeatTASKrggEdqx5L+GAYcYJOKtW1ys2Cp4pPUqcH0LsFw0Ywx61PdSZhG0gmqt2AyBhxTbWQMQDzQZONiZHwnzA7qVFYPluQRmpFVWfB61MpVCVf0qWRJ3GbhtLKfwqGMnef9v9KfIVKHZUkIWNPMk7VNzKV7GlZRGIKWOcVpRPkHnrWTaXayEZ6HpV+JlD9ah3OCqncstTGp5pjd6kzG4yM0ikZ6Uq/cpAO9IaHsMrxTDxTgc0hoHYB0pkjjGMU4GmOAetBQhHGQarvjJyOasZ4wKhkHJz1pAisxYHrRTiOaK1RLlqPHWplqEfeqSsAJQeKZglqUGnKRQJj+1NNOHJwKa3UigViJhk0o+UUU/hvwoAbupQx2UECnYAGKaExVOVFPFNxhRTlp3ENwfP3dqcep96XGVwOtIRlqYDwP3R9aoQv++Zcng+tXzyMCqsdttuGduQaRUbdSVJFd9vWpZFzjioYYdsxb1q4RxmiwNjYsoOlOWMMd/cU8cj2pEG3NMkcBil3U0nNJtOc0APqRelRg08HApgOHSikDUZoAdmg00c0vSgAqTFR0uT60AOYYpKTNGfagApaKKAEpO9KTTc80AP7iqOo3H2ezll9eKuM2FJx2rJ1sF4EiHQ80yoasznZI7aLn5jyay73i5Eq8jFWdQACKM8hapBy1vt/jPQmtoLQ9SlHTUoJM0s8qsOvSqT26G6BX/WA8mr0iGGQ7hztzkVV02MzyGRjwSao9GEUldEF9ZGd8Hk9sU+1ia2tk9c1pDbBMS2Cv61n6i7RkBWBAOaCk7mhBI7ocihIQg35PWm2MoaEFuM+tSowGVfn0oOepdMvpgrkcDFREh0UKd341bghadQAy7SMfSormOLTU+U75D0x0qWcqd3YRIhH+8lOG7LUMwcjLH8KiLu6+ZKw809AOgqGSTMZy3zCkkaqm2XrV3VwCBjtXQW3zICetcjbTsNvPXua6XR5jIdp+b6UmjkxNOxqkUw1IxFRk5I9qyOARuExSRknrSsMmkU889KVxoccA5FMB5pzAYyKjxQMcetI3SlzSN0oGMNRt1p5NMPJoAZiilIorREO9xoHeng5qNTTqwKJV6inHnpUYqRSAKAAZXk0kh7+tLkd6azD0oASlphOTwaCeRg0EinNPU55qNjT4/7o60CZKrDvThz0qHO04PWpUyR1xQIevSk/ioTvQ1WA8U4KKjWnA+9AD8AdKN2TimZIPWl3e1AEoPFLmmfwig52nHWmIfQDTC2cClzhqAJgKKQNxS5oGGaM0hNJmgCRTTqiDU/OelADqKbzRmgB1FIDRmgBc0oNNyKUGgANMHWnE0zvQA/saytWYeeq+grTbJXrisbXsJdRtnA20F0l7xjXU0Zn2k84qrcEL5e3pmqd1E73YdWPB5qdWEkiqegrqWx66Wgak5cHaP4P6Vj2UjQwqV9T/Otq42lZMHtisVmGECDHJyKT3Oyk7qxcP70bm61k6hu89wDkCtAsSwwcEdqz8mW7ljfr60GqjoWrW6C2G5h9zNZ/wDal07iXYRDuxnFXEizbSwxjJ296hjvoBoBsQm67MmDkdBTkYTlybnUaS5ayaR2YK3Qiqs4CAtGzOc96t6SPL0ZUc4IHSs+aYKxJ6VDMKUeaQx5iHyTz6VDCfNZgDUCMZJCdxNPXMbLs49cUzt5dC/BGCu3PNdBoJELYHJrnoGDOCPxrX0vcLjIJxRLY8/Fr3TpTnPNIWFPJ4qNsVzM8cNwpmeaWopW2jjikioomJqNgT0pkb571MOlMqw0cKKbuycU7OSaYeGoARqYDyacxqJjyaBCk80VHmirQAuSeKcDUFnJuBz1qdWxwRWbQEqEEilPJGD1pqjJyOvpVS91W1t7yztJSVubj7i+vX/CpAvLggc1G7AZHOaSMPvORj0oZfmNAhE4HJp3U8U1Y+OtCrg0Ej2HFOj45PWmNmpFoEx5wcZ609OnFMHNOBxQIevrQ3IzSDrntTm9ulWAgpU6mm0MhLKc8UAS8E4pcAjNQys24Ko49afk4FAEmRtFOU9qaCMClyo6nAoEJIQsZbpj1qOzkEsIfOeSM1IcFSG+ZfSkiRETEa7Vz0oAmBGMDrS4NRjqKkzQAh460ZoPJpKBijFLu7Co805eaAJBuNJmgNSUAOFIz7QxPbrSA4x9aZcnEcn0oAmzxn1oBpqZ2j6U7igBGbFIDmkkoToKYEm3NYfiiM+Ssi9BxW72NVNRgE9o6HqBmmti6btI40xNkYxUDKIt+7hsilv5JoYw0QJIODVaVpJlJcYJxXRF6Hs0mpInAUTqrHPHOOazr+MRSgxAkZqWZ/s6Lg7mPWnynBUkZFB0wXKYU88jzkxhht68Ve0yFizSSA726VfjtY2cyADNXltwqg5ANMqVa2hDHAixZxiTrVOOwhW484RjeTWlcZ8s7eTVdXYRKMc5pvU5+ZyLYYCAg8AVh34YxHYRgmtFmZo3FUZoj5JbPSoNqCsypCpiwamjkzn0NRbw0WTxRuHlcdaR2SV1qaFr8re55rc07JZSO9c/Yndx3xW9pzYCL3zTlseZi0rHSg7gMUYOaMbRRng1zM8WwhGKhucYpwyG5olXcKQ1oVkO0M3JAGTip45A8IkAIB9etJEu1jkZBGDUhYAYAwtMLsTOCc1Gx5px5phGaAGk1GwJJp7Kab60DIjkGihutFaIdhIoCh4OKsBePWo+3BpULYrNiH7e9U73S7a41Szv5sNNbD90T1T6fnVkNuOKcWUHaVyPWpEyUElmb1NNfrQhyPYcCkcikIbmjODRR3pkjzT6bgkcU4UCY5M807r0pq8Zp3A6UhEowBRximZpc1YDuKXH5UwZp2fWgBy46UoxnHakXHUdaOc0AKPvYHSndDTAfnp/vQA4U400UE85FAhTS5GKZuwaTPNADxS0gYUE8UDE4zTuBwO9RZ5pxIoAf060oNRbs9acDQA9iBjikkw6kEZB60uARzSAYNADgTjr0pQabmigBW5pvSnj3qNzTAnVsrTZOh96jVqeGBHWga01Oa1G3WO6ZQAqNyBWPc4Zti9R1NdZq9r50O9fvLXNJb/PKe9awZ6WGqaGFdAhxxznrVlpVjQBuRT72M/d285qnJHnhu1aHpwaki5HKHjLJ2q26lowT1qjAPKQbec1fWZHiBz060GU1qAUiInbULNiMDODT7ifKhlOF6YrIn1Dyp9rj5TwDQTGm9zVnA+zhhwTVGUnaMDjHIrS8vzrEMOuKpIrDJkGAOKRdKdmZDjexX7o9KUIR3qe9iy4delNR/n+bpQdrldFuzGHUjg1u6auZgT2rHtVw+7+HtW9pS75QF5olseZjHobzEYOeuKgikLdT0qTnec9KjRACa5jxx8rccdaQBsDmlK+tKTxxQAgIXJJxkVA8meF5FPYnByMiqoyX9KDSNupZTccbqceOaYzbUB9O9J8xUH1oJYbjzmoiTk5NOkOKYxyMigBjdaKBRWiKHKeKGbauaQKQKaxVhtI5rMkfFzzTj1pIRgYNSbecnpUsTHJ0pxWgLgUb8UCG4pCOacpJLZPHakzmqJFDYpwNR4p3Q0mBKDS00Z2Hb1ocNvjKthP4qkB+aUHNIw9KEByc1ZJKtA6nNNBpTz1oAM4PHSnA5poGRg9KcBjpQAuOadnjFJmhetAD+1NGfwp1A6UAIcbT61EG5xUrAYNRY5z3oAeeoxTucVGGbNPJOKAG04dKQYxzSqeDQA008GkIBpo60ATA8U0vigHiomOTU3GiUGn5qMU5OvNCYMdmmtSn2pQMjmqEIoyKBwaVeBSZyeaA6DpAGXB6Gue1S1aJiYxwa6E4xUU0YlUqwzmmbU5cpyDRB1O771Z1yn8GOveuglthFO6SdT0NUL62wqkdRWsWelQrdDLRTChDHJHSnDKjr15xUVzMysdxyRTo5DK6kqcVodu+o3mSQ5OFAqhc2omnG09DmtOSLc2F4Y96hsrNo5HMhySeKCZSsjdh2Q2KBuuKoTYcNjirF7geWgBxjmqkinb8p5pGNPVlSYjG3FRiMFsCpCMkhvvURqVAbvQjq5rItWwIdVxXRaLEPmc8YrF09GeUH2rpraERwgDgt1qKjPLxVS5KTTc80Him5GaxOAkJ4qPmlLDFByRxQNCbd3BoWMKc07GRz1pQ3YUDI5Bnj1pgbjHpUzdc9xVZ+G479aBg/NRNkcVLJxjFMOTmhDIhmikD0VsNEu/IwaZ5Z37scU7jHvTo/u1iyCRccZpwO449KaF70sf3jUiJCxPAFRkHOfSpEIBNRkkuaBDZAWKlfxqQHNNBxxTlwAaoTQUvemnJ6U/GKTEPGdvBxTlQbdp5z1qNTUimpAcD2pcim0q96dyRaUUlKKaYDh1paTtSimAopQRmkNNPFK4ElKc1GrGlLGlcErilh0zScUhINC0XHYUcGnEjHWmmk70XCwhJzgU5etRyHbyKjiZiTk0XCxcBA6004FMcZGQaUfMKLiYhPFNU89aHB7URqCeaTGiRf0p5I2jHNRZxxSg9qBkgI9acrDB5qGn8YFO4rD8/LTB1pBnPtS1SYDwaU/d461Fnmng0CKl5aCaIkH5hzmsO4iZ1OeGXqPSunGMEVQu7cABlHLdauLOinU5WcZLb+Yz54z0oRWW3ITkitm4gUMwxj0qlcWrIAqn71apnqQr3RTslYwsxOWBq5GnzoD3FKLQ28atng9aniwQ0hHAHH1p3CUrkUx/fHI4A61nTS+Tyxxmrpy5LE1RuU85+eg4oLpJIYCGXeDkGpotsn3eaSKMMu0cCtGwt1KjAxt6+9Jjqzsi1pkALKRW2wGSFbIAqtZxqrAjgEVP3bFYzdzx6knJiMfWm4znFLJSA8VJFhAp69qeTtxim5xxRu29eaAHZOM03IHNGc01qBoVidwx0PWop8BgF5FPB4pjDmgoZI2QKaWOD6U44qNz8uKYEIx3opduaK0BMnUAjJqRAM1V3EHip4jWTILGe1AUA5pmeRTs1AMGGGyKTdg09QCpyRmonUjmmIM5bmlzk/SotwwOeaep4qhMmU4pTktioxmpN2GpMlCqBk4p2KRRgk+tOpDHdhSrSUqg56UiRaeBxmmU8fdpoBAcinA0z+GhTVAOLHJFI+dp29aT+I08GpAUdB60OQMDFMLYBPYVg614gisF+Z1z9aLFwpynojcHJYr0FPXOKztG1CPULRZI2U7uuDWj2xQEoOG4uaQmot3NSAjHNISElBaPiq+/GFqyBuOAcVXmj+cHpigaJo8gU6MlabB8wxTyMUA0KehNMBINAPNK3tQITvmlB+bNJQaAJe1AOAc9e1NzxSggleRmgAVjjDYp24UrANyD0pu2qQmKADzTiBim9BjNAJz7UxCHinAhlKsODTW+lOHCgY5obsGzKF/Zh0OzOR0rLu4jFAJGB3jp6VvM+089KiljSddrDikpM6YVLI50SyXRRcDb34qW4URReXj5B8w9c1pyWqwEBF4Pes69PzmMYPFbRZvTncz3+bkcVAUDHAPOe1XNpVcPTY41D4A681odMZWZCkWHCn7vtWzZQfdwPlqraQktgjLelbUaCKNYwOayqOxzV6utiMsfPCqOBUucNjuaTYAxbvRxnd3rPc5WIx/vUzJz7U5huqNj2oEPHJzQDzTFNOHHegGOA5zTWpxPFRMaBoU5Xk9DSMdy0E7lANIflXg5plEb/wCzUTNzx0p7/L+NQMCGNA4rUcDRTM0VoUkTAc1Oowue9Rgc1MmMZrIyFUcZPalweo6UE0fjUsTHpgimSk4OKAeeKVz7UhEEagDDdaftwcilAGOetIp2Ke+asBdxqROetRKR+NPZgHwKBMmTvTqYrelOBoEPBpxYioQTmng1JLRJjuaQODwO1DHK+9QQoVck9zSEkTZ5welGcdKV+aaKBijnmnbtoz6U2ndVOaNwSMLVNSMcbqhwa8o8WyXV3d7Vc113i+9it55QHPyjNcTa6ml5N5pCkjIrphGyPcw1NRidd8LdS2QyW075kU8A16dCwaPd3rxTwzuttWa4AG0tkjtXrNhc+dAhHQispxsc2LpWfMXVbMhFTIAWqqiky5qxgocjvWZwMeMBjiopeWpQMHOTQ3LUErcWH5ae1MANOySOaChBRQO+abu9qTExaKKKEIM05Q2PujI5H0pAoqJVm+2eYHPl4ximBZU4BPc0u41GrNznGM9aeDmqTAByad2qMtg0oYnincB+aM03FHegCOQfMKQcdKdJyppqKe9JgJMDJGFHXrWNPH+/ZehArfwOMdazdTtzKdycMPTvVI1pysZpjDdeacqp6dKi/eRN8w5qa3jeRvu8ZrXm0Op1EkaFhEFXzSPmqweJM0oIVAMAYpM5FZN3Zxt3ZHIcMT61GMk1I5Hemb1QZPSkITcQcUMAQCOtHGMimKTuNBQoOKU0h5pM0AiTOFFMbmkLnAGKUdKChG+6KaOlDt2ppbBxQihkh3GonbHPrUjADJBqB+QPatEAlFLiiqBFo8UqNTVUU4cVizK5N2NNzSdsDrTkHHzUtwFU5NKe1CKhye9Ru3ltkGkhdbD3GeaRGGCT2pqy7uopSASCBihO4ddRyBc7sUo2l84pFOKWqJvceCCTipBUSmnqaAGOGB4qWIHGTS0VIxw+Y5pQ27timhsUFs0ibCk84pMimkZpMCgLEh6VImMGoAoqRVB6U1uVa55j43t41+1Sv6GvLbCXbK/lZCg16v8AECN9rxlcq9edJYoGKQj5+9di1R7NBNpM6Hw+7SqpJ4zzXq+gbTYDA5ryTwtC8l3g8Y4zXq2ho0UYBes6i0FjVobca4wac5zQBtHXPejNcx5AlITg0hPNBGeaBWHhqaXwaM4ozQMUHNKycUinJxSN97b2pMVhaRjSUmM0ILDlNPJJUBeB3pgAFO3cUwsJIcyAr90DFKDSUUCFNKOtIcbR60vOPamA6ijPy0gNUAp6U0HFLmm0guODY+b8KDjk+tNPWkpgtCN4Y25deaRFVfujAqQ00UXHzMSRx0IpF6UGmr0pJDvca+MEGo5QHTaKcy5/Ck3baY7CL0ph4opGGRRYAzS01Dk4NKTzRYaBugpQeKTOaOKChH7VG/WnM+CRURJqkihN2TikYVGc7s0pOapANJ5opD1opiuWXOwZzkUJKrcg8etQ3D7LZmbpVS3kBI2/crJjjTurmunzEY6etTr6ZzVaFsphamBwuTSRm1ZjzwMdPeub8UaummwBictngVviTcjetcL4/hluEilRMqhANawjcujG8tTQ8N642pDMeODgjNdZnI55xXnnw/tZFM8pG1S3Ar0IE7RkY4rOasx1kubQUc0uaRKSg5+Ww8HinpyuagJwyj1qXOOKAJEfcDxShuM4qFD82KeW2nFSApb14pC2OgzUVwflyKWH7oJ9KAJw2V9DSc+tN75ozQAoY7iPShpGBAAx703oc0u8GjYtWsZfiSzjuoRuXOB1rzz+x2g1CTYpIbvivVZY/MiKHrWTc2ylowq89K3pzOuhXcFqcjFZCytlKj94zfnXZaRG21FbPTOapT2YeWHcPutW9aqFJx2FOpPQeIq85a6YGO1IWANN3Zx9KY4Oc1zbnGyU49aUNimKM04jGKBAeTSUUrHNAAGxxSluKYBg05ulJgGaAaSihAKee9Cnnk0maCu4cUwH5pajHHBpc0CZIcbelIDk47UgNK3C5piHHgU0cigHIpueaoCTGBmkBzRnikWgAPXpS0jtgUxMnmgBzcGkPFBORmm5zkntQAdevFM4A60jtu4FNINBUQP1phxQTimE0FBz6U188cU/IprsKYDQcUdc80mM0J6UAhM84pfxpHFNoKFcYwRzmmnGcUB8Zz2puMndVFCE5zxUecjPSnScGozwcU0A0tz0opcUUyRb6PzLcxjvzUNjGFwD1FXlHyHPJ9abDEA5OMVDKjKyJ4to+tSyNmPFRKACcCh+R1qVuZ9SBJBGrbu5qlNEk5bPINWblcx9eaLePagJ5qpG/NZEen2UMGNi4rTY8Co1J9qU5qTnY7NSBs1DzSqcGgklwCDmnpynFM+8pGKjEnlfeOKlq4JcxPzSM5A5FZzX4WXbnOe+avo4cDmq5bFOEobjJG7mnpyAfamTru4WhMgAHtQGhN2pKapOcdqdQIOQCe1RpIC2O9PyfmHao0VQSe9AFknpUVwm45HWn9QDQxz0HNA0Uxbc5bqKsyt5Ma4pRnOW5p0qiQD2oKuOjfGPenMOpqFVOBUrH5fpUiGinjoaYvTPSlVs9qQg6GnZprn0pQM96BgT0pRTcUqmgQ7vto6HFIG9uaXt70AFKyY5pKQ5P0oEL2xQvWk3cYxQvWgB7CmYwacx96Z1PWgCTPFN34FITgU1fmGcUAKD8wp+aaAPWimA7POaGOaaTxjFIDjtQA8Nt4pHxQ33c1ApLNzxjiqAftwc01zzTmOPemMQT0xQNBnIqN6exwM4qJ2AIHrQMRTSA8mmg4pAaYxxNNpGIpce9BSEPSoz1qQ9Kj6mgYopWbjFNbgUztVADGo26mnNxUZb2poaENFNLe1FMdi7uxCXWpEfcinvUa9MdqeR8oxWb1MSUYAx3NIynbQGyBS0gKsiktip4lAUA0rLkcU5fu47027jcrjiAKTIprnaKrq+5qViXqWsijIzUbngUoPz0E2sWUOASOgrJ1abcCAcVeklSPIY4z05rn7y5P2nGPlq4m9CDbKjiRZAxNaVtelduT7VRuW44pkRHrVtXO+ULrU6iOXeAakPzHiszT5hsxnJrSjkEaknv61ly2PPqR5ZWJFOBinZqJG3fNTlPNIzeg9iAPrUbKRSt940DrQIfGcDmn7gaQHimMRQBIOTilzg4qJCOxp1AEhYU3k9KQdaHOKVhhxnnrTui00MCKQPk4pWAfGN1PXpUZO3pS0hik4zTVPNI4Jximk4Hy8mgCUU7OBTKa+Tge9AiTcKcD8h96YBtGKQnFAWFT5QQakUimryKWgQjDJNMII5qRj0FNfHfpTAax3DihWPbpSJhSfLO4HrThjHy9Kdh2FbBU+tIpx1pvenZpWCw4sDSEg0gGafjinYLCDgYNNKDPvRmgmmIR1YDgdKgWUN0qVjwRmqpTY1A0Su2E571HINzLipcggUyQelAxjjFRZJqVenNREgMc96YxjZpwBFIx28gZozmgrYevORTG4NKKYetOw0O60w8HFB60h5qrAD9KixxUrLxULcEinYqIhFFFFBVy4OlODALmiiszmFi5Oe1S0UUgFUgDmkHUntRRQMjkBI61BGhVjRRTETH5jgUoB3ZoopxFIjvLcypuzgr0rlL6RxIwHUUUVqjvwgRy7gA2c01i6P14NFFWjsexq6Lukl+la1w+3IOcZoorN7nn1174lvcKBtwatx/NyKKKhmMoqw8g8mkHIPtRRUGRIoOKQqCOetFFACog6ilPFFFACjrSNyKKKBjRgClQj3zRRSYDyM9aUUUVIxGJxxTVGDmiigQ7cKAQaKKAHZBHvTdpNFFADlPOKdu5oooAYQS9PbiiimgK6xCJy6k89jUucruooqhidaaGGcUUUCANyacJM8UUUDDFBFFFBJHIdtRurE9RRRQNCFsECnt93NFFMZEw9KYVB60UUDQ0g/hTaKKaKYvSoycNiiimNCsMUwtRRVAIWyKYQetFFA0NxRRRQUf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bradley M. Urine crystals: Identification and significance. Lab Med 1982; 13:348. Copyright &copy; 1983-2012 American Society for Clinical Pathology. Copyright &copy; 1983-2012 Laboratory Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_1_18448=[""].join("\n");
var outline_f18_1_18448=null;
var title_f18_1_18449="Angiolupoid sarcoidosis - cheek";
var content_f18_1_18449=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F70564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F70564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Angiolupoid sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 212px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Well demarcated, erythematous plaques on the cheek with numerous telangiectasias are characteristic of this clinical variant of sarcoidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_1_18449=[""].join("\n");
var outline_f18_1_18449=null;
var title_f18_1_18450="Perforation partial SBO";
var content_f18_1_18450=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small bowel obstruction with perforation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan demonstrating partial small bowel obstruction and perforation of the small bowel by a chicken bone (arrow). There is dilated small bowel in the left abdomen and collapsed small bowel in the right abdomen. Gas is present in the colon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Anthony Samir, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_1_18450=[""].join("\n");
var outline_f18_1_18450=null;
var title_f18_1_18451="Benzonatate: Drug information";
var content_f18_1_18451=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Benzonatate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/29/27091?source=see_link\">",
"    see \"Benzonatate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tessalon&reg;;",
"     </li>",
"     <li>",
"      Zonatuss&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F140023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antitussive",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F140012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cough: Oral: 100-200 mg 3 times/day as needed; maximum dose: 600 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F140019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;10 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F140013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F139996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zonatuss&trade;: 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral: 100 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tessalon&reg;: 100 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F139983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule (softgel)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F802613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Swallow capsule whole (do not break. chew, dissolve, cut, or crush).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F139998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of nonproductive cough",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F140021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, dizziness, hallucinations, headache, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, skin eruptions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, GI upset, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chest numbness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Burning sensation in eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Chill sensation, hypersensitivity reactions (bronchospasm, laryngospasm, cardiovascular collapse)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F140001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to benzonatate, related compounds (such as tetracaine), or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13118899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Severe reactions, including bronchospasm, cardiovascular collapse and laryngospasm have been reported. May be related to localized anesthetic effects due to sucking or chewing the capsule.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Psychiatric effects: Isolated cases of abnormal behavior including mental confusion and visual hallucinations have been reported; may be related to prior sensitivity to related agents (eg, tetracaine, procaine) or interaction with concurrent medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Accidental ingestion and potentially fatal overdose of benzonatate has been reported in children &lt;10 years of age. Signs and symptoms of overdose (restlessness, tremors, convulsion, coma, cardiac arrest) may occur within 15-20 minutes after ingestion. Death has been reported within 1 hour. Not approved for use in children &lt;10 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F139991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F139992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13118898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F140016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16257739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if benzonatate is excreted in breast milk. The manufacturer recommends that caution be exercised when administering benzonatate to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F140003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Benzonatate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $101.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $197.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Tessalon Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $292.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Tessalon Perles Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $148.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Zonatuss Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $180.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F139994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor patient's chest sounds and respiratory pattern",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F140004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Tusitato (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F139986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tetracaine congener with antitussive properties; suppresses cough by topical anesthetic action on the respiratory stretch receptors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F140000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Therapeutic: 15-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 3-8 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Mongan PD and Culling RD, &ldquo;Rapid Oral Anesthesia for Awake Intubation,&rdquo;",
"      <i>",
"       J Clin Anesth",
"      </i>",
"      , 1992, 4(2):101-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/1/18451/abstract-text/1562332/pubmed\" id=\"1562332\" target=\"_blank\">",
"        1562332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9098 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_1_18451=[""].join("\n");
var outline_f18_1_18451=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140009\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140023\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140012\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140019\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140013\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673296\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673297\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139996\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139983\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802613\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139998\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140021\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140001\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13118899\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298843\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139991\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139992\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13118898\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140016\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16257739\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140003\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139994\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140004\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139986\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140000\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9098\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9098|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/29/27091?source=related_link\">",
"      Benzonatate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_1_18452="Bronchiolitis obliterans II";
var content_f18_1_18452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchiolitis obliterans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bronchiolitis obliterans in chronic lung transplant rejection. Photomicrograph of chronic lung transplant rejection showing granulation tissue within the lumen of a small airway.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of L Kobzik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_1_18452=[""].join("\n");
var outline_f18_1_18452=null;
var title_f18_1_18453="MRI CT Huntington";
var content_f18_1_18453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F66811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F66811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI CT Huntington",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On brain MRI, T1-weighted (A) and T2-weighted (B) axial images show caudate atrophy and enlargement of the frontal horns. On CT, an axial image (C) from another patient shows similar findings.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eric D. Schwartz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_1_18453=[""].join("\n");
var outline_f18_1_18453=null;
var title_f18_1_18454="Collateral circulation around the shoulder";
var content_f18_1_18454=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Collateral circulation around the shoulder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 549px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The thyrocervical trunk, dorsal scapular artery and internal thoracic artery provide important collateral channels of blood flow to the ipsilateral brain and upper extremity when a significant stenosis or occlusion of the brachiocephalic or subclavian artery is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_1_18454=[""].join("\n");
var outline_f18_1_18454=null;
var title_f18_1_18455="Evaluation and treatment of taste and smell disorders";
var content_f18_1_18455=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and treatment of taste and smell disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/1/18455/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/1/18455/contributors\">",
"     Norman M Mann, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/1/18455/contributors\">",
"     Denis Lafreniere, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/1/18455/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/1/18455/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/1/18455/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/1/18455/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/1/18455/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many individuals with olfactory disorders report a decreased quality of life, particularly those with severe olfactory dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/1\">",
"     1",
"    </a>",
"    ]. Olfaction plays a significant role in our detection of the aroma and flavor of foods. It is also responsible for our awareness of fragrances in the environment. Disruption of the experience of a pleasant sensory exposure can sometimes cause depression. Patients may no longer look forward to eating and drinking, and they often refuse to go out to dinner and associate with friends. Important nutritional deficiencies can lead to marked weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/2\">",
"     2",
"    </a>",
"    ]. Additional dangers associated with olfactory impairment include the inability to detect the odors of spoiled food, smoke, and leaking gas. Furthermore, the importance of olfaction cannot be overemphasized to certain professions such as chefs, perfumers, and fire fighters [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/3\">",
"     3",
"    </a>",
"    ]. Some individuals with olfactory disorders find it difficult to function in everyday life [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of patients with abnormalities of taste or smell requires a multidisciplinary approach which may include the primary care clinician, otolaryngologist, neurologist, allergist, and oral consultant. The approach to these patients is reviewed here. The anatomy of taste and olfaction and the causes of abnormalities in these areas are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13801?source=see_link\">",
"     \"Anatomy and etiology of taste and smell disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY AND PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of features in the patient's history can be useful in evaluating disorders of smell or taste (",
"    <a class=\"graphic graphic_table graphicRef56441 \" href=\"UTD.htm?10/15/10493\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68168 \" href=\"UTD.htm?37/12/38092\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Head injuries [",
"      <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/5\">",
"       5",
"      </a>",
"      ] or viral infections [",
"      <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/6\">",
"       6",
"      </a>",
"      ] often produce",
"      <strong>",
"       sudden",
"      </strong>",
"      smell loss; in comparison, allergic rhinitis, nasal polyps, or neoplasms are associated with more",
"      <strong>",
"       gradual",
"      </strong>",
"      onset [",
"      <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Impairment that is",
"      <strong>",
"       intermittent",
"      </strong>",
"      is often seen in allergic rhinitis and the use of topical drugs.",
"     </li>",
"     <li>",
"      Associated symptoms such as headache and behavior disturbances may indicate problems with the central nervous system [",
"      <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, occupational exposure (chemicals, toxic fumes) and tobacco and alcohol habits need to be explored [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Allergies and medications also may be causally related (",
"    <a class=\"graphic graphic_table graphicRef81856 \" href=\"UTD.htm?15/34/15916\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef59575 \" href=\"UTD.htm?25/35/26174\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Subjective complaints of taste or smell loss need confirmation before embarking on an extensive evaluation. Many individuals confuse the ability to perceive \"taste\" and \"flavor.\" The former is related to the ability to detect sweet, sour, salty, and bitter. The term flavor involves the combined features of smell, taste, irritation, texture, and temperature. The smell or aroma of food and beverages is the most important contributor to flavor; as a result, derangement of smell is often described by patients as a problem with taste. Total loss of taste is rarely seen because of the anatomy and redundancy of the taste system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13801?source=see_link\">",
"     \"Anatomy and etiology of taste and smell disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination of the nasal cavity and paranasal sinuses by an otolaryngologist is essential since diseases in these areas can be responsible for a significant number of chemosensory disorders. In addition, a careful neurologic examination may reveal mental changes or peripheral nerve difficulties; olfactory complaints are occasionally the first symptoms to draw attention to a more serious neurologic problem [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The allergist plays an important role in the diagnosis of allergic and nonallergic rhinitis; evaluation of sensitivity to features in the home and work environment is essential. Skin testing may be necessary to confirm sensitivity to specific antigens.",
"   </p>",
"   <p>",
"    Dental prostheses, periodontal disease, intraoral lesions, and the distribution of taste papillae are all important features of the physical examination. Many oral conditions such as fungal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/11\">",
"     11",
"    </a>",
"    ] and glossitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/12\">",
"     12",
"    </a>",
"    ] are associated with taste dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of tests, including those assessing smell and taste and more general tests such as imaging and laboratory studies, are performed on the patient with abnormal smell or taste. Primary care clinicians do not often conduct smell or taste testing in their offices. An occasional clinician may do some superficial testing such as using chocolate, turpentine, coffee, or moth balls to test odor sensitivity. An efficient office test that could be used is the University of Pennsylvania Smell Identification Test (UPSIT). The test involves 40 micro-encapsulated odorants that are released by rubbing with the tip of a pencil; identification of the odor is made from among four choices.",
"   </p>",
"   <p>",
"    Another easy to use and reliable smell test has more recently been developed. The test involves use of the \"Sniffin sticks\" test (or TDIT-Threshold, Discrimination, Identification Test). One group reported that the technique only takes four minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/13\">",
"     13",
"    </a>",
"    ]. The test was used effectively in an analysis of patients with Parkinsonism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/14\">",
"     14",
"    </a>",
"    ]. Sniffin sticks can be obtained through the Department of Otorhinolaryngology at the University of Dresden Medical School in Dresden, Germany.",
"   </p>",
"   <p>",
"    Referral to a smell center, where more detailed testing can be easily and efficiently performed, is indicated when important defects are noted on any of these office-based tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chemosensory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of quantitative psychophysical tests are used to evaluate chemosensation. These are threshold tests which determine the",
"    <strong>",
"     minimum",
"    </strong>",
"    concentration that can be detected. The ability to discriminate and identify taste and smells is also assessed. The patient is interviewed by a taste and smell technician at the beginning of olfactory testing. The details of the taste and smell complaints are noted, including the date of onset, the degree of impairment, and the circumstances at the onset of the difficulty. As an example, a history of viral infection preceding the problem would be of value in diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Butanol threshold test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The butanol threshold test evaluates olfactory function [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/15\">",
"     15",
"    </a>",
"    ]. This test uses N-butyl alcohol, a sweet smelling substance, as the odorant. The patient is presented with bottles containing either water or odorant in an aqueous concentration series ranging from 2 x 10(-7) to 4 percent. Each nostril is tested separately. The point of transition between detection and no detection is determined and the threshold concentration is converted into a numeric score. Appropriate tests are included to identify possible malingering, particularly in litigation cases.",
"   </p>",
"   <p>",
"    An odor identification and trigeminal function test also are administered [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/15\">",
"     15",
"    </a>",
"    ]. Eight different odorants are presented to each nostril and the patient is asked whether he or she is aware of a sensation from the odorant and if it can be specifically identified. Odorants that are irritating are used to assess trigeminal function in the nasal mucosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Whole mouth taste test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whole mouth taste testing assesses the patient's ability to detect, identify, and rate the intensity of various concentrations of sweet, sour, salty, and bitter taste solutions. Magnitude matching (comparing perceived hearing tones to taste solutions) is used [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/16\">",
"     16",
"    </a>",
"    ]. The patient's data is compared to data obtained from \"normal\" control subjects and is assigned to a percentile",
"    <span class=\"nowrap\">",
"     score/rank",
"    </span>",
"    (number of subjects whose responses are below those of the patient) for each taste quality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Spatial test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spatial testing is performed since localized losses of taste often go unnoticed. Function in the different taste bud fields is assessed separately with regional testing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/16\">",
"     16",
"    </a>",
"    ]. At our taste center, a cotton swab soaked in a specific taste solution is separately applied to four quadrants of the tongue and to each half of the soft palate. Taste function in the throat is assessed by asking the patient to swallow a portion of each taste solution. All of the regions mentioned are independently tested with each taste solution; in each case, the patient is asked to identify the taste quality and estimate its intensity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Flavor discrimination test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flavor discrimination test is used to evaluate the combination of both taste and smell sensation. Four different stimulant solutions are made available which differ in the amount of sweetener present. These are presented in a random order and the patient is asked to taste the various solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Somatosensory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of somatosensation in the mouth is carried out by the use of Semmes-Weinstein monofilaments [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/18\">",
"     18",
"    </a>",
"    ]. A patient's contact detection (pressure) threshold is determined by applying a Semmes-Weinstein monofilament which exerts a force when applied to a peripheral nerve field proportional to the gauge of the monofilament. Various areas in the interior of the mouth are tested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is generally performed to image the brain and soft tissues. Evaluation of the sinuses is often not complete without an MRI or CT study since mucosal edema can cause dysfunction, which will not be revealed on plain x-ray. Computed tomography (CT) also is useful for studying the skull base, cranial contents, sinuses, and nose. Chest x-rays are occasionally ordered. There has been one case report of a lung neoplasm that presented with complaints of dysgeusia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete blood count, sedimentation rate, plasma creatinine, liver function tests, antinuclear antibodies, and a thyroid profile are an essential part of the initial evaluation. Detection of antibodies to",
"    <span class=\"nowrap\">",
"     Ro/SSA",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     LA/SSB",
"    </span>",
"    may be valuable in identifying patients with Sj&ouml;gren's syndrome, while measurement of lead, arsenic, and other heavy metal concentrations may be warranted in selected patients with dysgeusia. Vitamin B12 and other vitamin concentrations should be measured in patients with suspected malnutrition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of taste and smell disorders usually depends upon the etiology. Nasal and paranasal sinus diseases are the most common causes of olfactory abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nasal and paranasal sinus disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive disorders such as allergic rhinitis, nonallergic rhinitis, rhinosinusitis, and nasal polyposis require relief of the obstruction and treatment of the accompanying infection, if present. Some patients with smell loss do not have significant obstruction on endoscopy or CT studies. It is possible that these cases are due to damage to olfactory receptors resulting from products of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/20\">",
"     20",
"    </a>",
"    ]; improvement occurs with treatment of the nasal sinus disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H290129756\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids reduce mucosal edema and polypoid elements, effectively treating the majority of nasal and paranasal sinus diseases. However, long-term use can cause a variety of adverse affects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .) Thus, these drugs are best employed in short courses of two to three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/21\">",
"     21",
"    </a>",
"    ]. Recurrent symptoms may occur after cessation of therapy, but often can be prevented by adding supportive long-term treatment such as intranasal glucocorticoids.",
"   </p>",
"   <p>",
"    Intranasal glucocorticoids were first introduced for the treatment of rhinosinusitis in 1954 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/22\">",
"     22",
"    </a>",
"    ]. However, these early agents had the same adverse effects as systemic glucocorticoids. Topical glucocorticoids were subsequently introduced that could be administered over a long period of time and were rapidly metabolized to inactive or less active metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/23\">",
"     23",
"    </a>",
"    ]. They exhibited no significant side effects and proved to be satisfactory for the treatment of rhinitis, nasal edema, and polyps.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"     Beclomethasone",
"    </a>",
"    dipropionate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33392?source=see_link\">",
"     flunisolide",
"    </a>",
"    have been used effectively in the United States at a dose of two sprays in each nostril twice daily.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36080?source=see_link\">",
"     Mometasone",
"    </a>",
"    furoate monohydrate nasal spray is a newer agent that is administered at a dose of 50 &micro;g (two sprays in each nostril) once daily [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/24\">",
"     24",
"    </a>",
"    ]. All of the medications are highly effective in reducing the symptoms associated with perennial allergic rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/25\">",
"     25",
"    </a>",
"    ]. One study suggested that mometasone furoate was superior to beclomethasone, but the results did not reach statistical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/26\">",
"     26",
"    </a>",
"    ]. Long-term administration (twelve months) of mometasone furoate has not been associated with adverse tissue changes in the nasal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inadequate drug dispersal can limit the efficacy of intranasal glucocorticoids. The spray should be administered in the head down and forward position [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/28\">",
"     28",
"    </a>",
"    ]. After the initial spray, the patient should bend his head forward and down so that the medication is directed to the proper area, particularly since nasal obstruction and impaired ciliary movement can block access [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/29\">",
"     29",
"    </a>",
"    ]. Alternatively, an applicator that produces a squirt rather than a spray may be used to deliver the drug higher up in the nasal cavity, to reach the localized area of olfactory mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A coexisting bacterial sinus infection is another factor that can limit the effectiveness of intranasal glucocorticoids.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     Ampicillin",
"    </a>",
"    (500 mg four times daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    axetil (500 mg twice daily) have been used successfully in our clinic when given in courses of at least two to three weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antihistamines may be indicated in cases of allergic rhinitis. Attention should also be given to factors in the home (eg, molds, pets) that might add to allergic problems. Desensitization is necessary in some cases. Leukotriene inhibitors can reduce the size of nasal polyps and improve smell in some patients with polyps and",
"    <span class=\"nowrap\">",
"     anosmia/hyposmia",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/31\">",
"     31",
"    </a>",
"    ]. Treatment of chronic sinusitis and nasal polyposis, however, has variable effectiveness for improving anosmia.",
"   </p>",
"   <p>",
"    In an open label, non-controlled, prospective study of 312 patients with hyposmia from a variety of causes (31 percent post-infectious, 31 percent allergic rhinitis, 14 percent post-head trauma),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    (200 to 800 mg) was found to improve subjective smell loss in 50 percent, with higher doses associated with improved smell function [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/32\">",
"     32",
"    </a>",
"    ]. Improvement persisted as long as treatment was continued, which extended from 6 to 72 months. Further research, including placebo-controlled studies, is needed prior to wide-spread use for hyposmia.",
"   </p>",
"   <p>",
"    Surgery may be necessary if medical therapy for nasal or sinus disease is ineffective. Polypectomy and sinus surgery are beneficial in many patients; endoscopic nasal and sinus surgery are significant advances in therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/33\">",
"     33",
"    </a>",
"    ]. The surgical success rate is high for symptoms not involving smell and taste. In one study, for example, the surgical success rate (defined as the absence of purulent rhinorrhea, post nasal discharge, facial pain, and headache) was 88 percent in nonasthmatics; the recurrence rate for focal and diffuse polyps and infectious disease was 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effectiveness of endoscopic sinus surgery in treatment of smell disorders, however, is variably reported.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, anosmia improved in 52 percent of patients with nasal polyposis treated with endoscopic sinus surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/35\">",
"       35",
"      </a>",
"      ]. Greater disease severity, determined by the Kennedy sinus disease staging system, was associated with greater smell loss and persistent anosmia. Postoperative endoscopic examination revealed normal mucosa in 92 percent of patients whose sense of smell improved, compared with 17 percent of patients with persistent anosmia.",
"     </li>",
"     <li>",
"      In contrast, a multi-institutional prospective cohort study (n = 111) found that patients with severe olfactory dysfunction showed significant improvement in olfaction after endoscopic sinus surgery, while patients with milder impairments in olfaction did not significantly improve [",
"      <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/36\">",
"       36",
"      </a>",
"      ]. The presence of nasal polyposis correlated with surgical success.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients may need to continue medical management (nasal steroids, antihistamines, and leukotriene inhibitors) in the postoperative period to limit mucosal inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Olfactory and taste impairment resulting from head trauma cannot specifically be treated. Rapid improvement may occur with resolution of edema and hemorrhage. &nbsp;Olfactory neurons do have regenerative capabilities [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/38\">",
"     38",
"    </a>",
"    ]. Regeneration can occur in cases of neural damage over a period of days or even years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A longitudinal study of 542 patients presenting with olfactory loss of various etiologies to a university smell and taste center found that statistically significant change in function occurred in 57 percent of anosmic and 43 percent of microsmic patients over time (3 months to 24 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/40\">",
"     40",
"    </a>",
"    ]. Complete recovery was seen in 11 and 23 percent of patients with anosmia and microsmia respectively. Recovery was related to patient age, severity of initial loss and duration of loss at first testing; etiology of olfactory loss, gender, and smoking did not predict recovery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Parosmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parosmia (abhorrent odor perception) associated with rhinosinusitis, head trauma, viral infection, or oral problems frequently disappears with successful treatment of the inciting conditions. Antiseizure medication is sometimes helpful in persistent cases. We have used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    in our clinic in several cases with some success.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Dysgeusia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of dysgeusia can be challenging. Improvement in the condition or conditions causing the dysgeusia often alleviates the problem. Where gastric reflux has been a significant etiologic factor, medications such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    have been very helpful. However, there are many instances where the complaint persists. We have successfully used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    in several such cases. Clonazepam causes brainstem serotonergic descending inhibition, binding more to central than peripheral benzodiazepine receptors. It has a long half-life and is well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/41\">",
"     41",
"    </a>",
"    ]. Doses range from 0.5 to 3 to 4 mg daily.",
"   </p>",
"   <p>",
"    We have found tricyclic antidepressants to be effective in controlling burning mouth problems. These medications are analgesics as well as antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18455/abstract/42\">",
"     42",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     Clonazepam",
"    </a>",
"    may also be effective in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of features in the patient's history can be useful in evaluating disorders of smell or taste (",
"      <a class=\"graphic graphic_table graphicRef56441 \" href=\"UTD.htm?10/15/10493\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef68168 \" href=\"UTD.htm?37/12/38092\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of tests, including those assessing smell and taste and more general tests such as imaging and laboratory studies, are often performed by specialists on the patient with abnormal smell or taste. Primary care clinicians do not often conduct smell or taste testing in their offices. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnostic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of taste and smell disorders usually depends upon the etiology. Obstructive disorders such as allergic rhinitis, nonallergic rhinitis, rhinosinusitis, and nasal polyposis require relief of the obstruction and treatment of the accompanying infection, if present. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic glucocorticoids reduce mucosal edema and polypoid elements, effectively treating the majority of nasal and paranasal sinus diseases. However, long-term use can cause a variety of adverse affects. Intranasal glucocorticoids such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"       beclomethasone",
"      </a>",
"      dipropionate and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33392?source=see_link\">",
"       flunisolide",
"      </a>",
"      have been used effectively in patients with allergic rhinitis at a dose of two sprays in each nostril twice daily.",
"     </li>",
"     <li>",
"      No effective treatment is available for olfactory and taste impairment caused by viral infections",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      head trauma. However, olfactory neurons do have regenerative capabilities and some patients have partial recovery without treatment. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Other disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/1\">",
"      Neuland C, Bitter T, Marschner H, et al. Health-related and specific olfaction-related quality of life in patients with chronic functional anosmia or severe hyposmia. Laryngoscope 2011; 121:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/2\">",
"      Mattes RD, Cowart BJ. Dietary assessment of patients with chemosensory disorders. J Am Diet Assoc 1994; 94:50.",
"     </a>",
"    </li>",
"    <li>",
"     Smith DV, Duncan HJ. Primary Olfactory Disorders: Anosmia, Hyposmia and Dysosmia. In: Science of Olfaction, Serby MJ, Chobor KL (Eds), Springer-Verlag, New York 1992. p.439.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/4\">",
"      Kimmelman CP. Clinical review of olfaction. Am J Otolaryngol 1993; 14:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/5\">",
"      SUMNER D. POST-TRAUMATIC ANOSMIA. Brain 1964; 87:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/6\">",
"      Jafek, BW, Hartman, D, Ellen, PM. Post viral olfactory dysfunction. Am J Rhinol 1990; 4:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/7\">",
"      Apter AJ, Mott AE, Frank ME, Clive JM. Allergic rhinitis and olfactory loss. Ann Allergy Asthma Immunol 1995; 75:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/8\">",
"      Bakay L. Olfactory meningiomas. The missed diagnosis. JAMA 1984; 251:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/9\">",
"      Emmett EA. Parosmia and hyposmia induced by solvent exposure. Br J Ind Med 1976; 33:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/10\">",
"      Frye RE, Schwartz BS, Doty RL. Dose-related effects of cigarette smoking on olfactory function. JAMA 1990; 263:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/11\">",
"      Guerrier Y, Uziel A. Clinical aspects of taste disorders. Acta Otolaryngol 1979; 87:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/12\">",
"      Brenner BE, Simon RR. Glossitis and dysgeusia. Am J Emerg Med 1984; 2:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/13\">",
"      Konnerth CG, Hummel T, Rosenheim K, Kobal G. Screening of olfactory function using a 4 minute odor identification test. Chem Senses 2001; 26:1088.",
"     </a>",
"    </li>",
"    <li>",
"     Kobal, G, Lang, CJ. Olfactory testing with \"Sniffin sticks\" in idiopathic Parkinsonism. Chem Senses 2001; 26:1088. Abstract.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/15\">",
"      Cain WS, Gent J, Catalanotto FA, Goodspeed RB. Clinical evaluation of olfaction. Am J Otolaryngol 1983; 4:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/16\">",
"      Bartoshuk L. Clinical evaluation of the sense of taste. Ear Nose Throat J 1989; 68:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/17\">",
"      Rusiniak KW, Hankins WG, Garcia J, Brett LP. Flavor-illness aversions: potentiation of odor by taste in rats. Behav Neural Biol 1979; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     Semmes J, Weinstein S, Ghent L, Tanber HL. Normative study. In: Somatosensory Changes After Penetrating Brain Injuries in Man, Semmes J (Ed), Harvard University Press, Cambridge 1960. p.4.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/19\">",
"      Panayiotou H, Small SC, Hunter JH, Culpepper RM. Sweet taste (dysgeusia). The first symptom of hyponatremia in small cell carcinoma of the lung. Arch Intern Med 1995; 155:1325.",
"     </a>",
"    </li>",
"    <li>",
"     Mott AK. Topical corticosteroid therapy for nasal polyposis. In: Smell and Taste in Health and Disease, Getchell TV, Doty RL, Bartoshuk LM, Snow JB Jr (Eds), Raven, New York 1991. p.554.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/21\">",
"      Myers D, Myers EN. The medical and surgical treatment of nasal polyps. Laryngoscope 1974; 84:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/22\">",
"      PENNYPACKER CS. Hydrocortisone alcohol in the local treatment of hay fever: a preliminary study. J Allergy 1954; 25:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/23\">",
"      Mygind N. Topical steroid treatment for allergic rhinitis and allied conditions. Clin Otolaryngol Allied Sci 1982; 7:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/24\">",
"      Stuck BA, Blum A, Hagner AE, et al. Mometasone furoate nasal spray improves olfactory performance in seasonal allergic rhinitis. Allergy 2003; 58:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/25\">",
"      Siegel SC. Topical intranasal corticosteroid therapy in rhinitis. J Allergy Clin Immunol 1988; 81:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/26\">",
"      Graft D, Aaronson D, Chervinsky P, et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol 1996; 98:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/27\">",
"      Minshall E, Ghaffar O, Cameron L, et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg 1998; 118:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/28\">",
"      Canciani M, Mastella G. Efficacy of beclomethasone nasal drops, administered in the Moffat's position for nasal polyposis. Acta Paediatr Scand 1988; 77:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/29\">",
"      Wilson R, Sykes DA, Chan KL, et al. Effect of head position on the efficacy of topical treatment of chronic mucopurulent rhinosinusitis. Thorax 1987; 42:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/30\">",
"      Scheibe M, Bethge C, Witt M, Hummel T. Intranasal administration of drugs. Arch Otolaryngol Head Neck Surg 2008; 134:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/31\">",
"      Parnes SM. The role of leukotriene inhibitors in patients with paranasal sinus disease. Curr Opin Otolaryngol Head Neck Surg 2003; 11:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/32\">",
"      Henkin RI, Velicu I, Schmidt L. An open-label controlled trial of theophylline for treatment of patients with hyposmia. Am J Med Sci 2009; 337:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/33\">",
"      Lanza DC, Kennedy DW. Current concepts in the surgical management of nasal polyposis. J Allergy Clin Immunol 1992; 90:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/34\">",
"      Lawson W. The intranasal ethmoidectomy: an experience with 1,077 procedures. Laryngoscope 1991; 101:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/35\">",
"      Downey LL, Jacobs JB, Lebowitz RA. Anosmia and chronic sinus disease. Otolaryngol Head Neck Surg 1996; 115:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/36\">",
"      Litvack JR, Mace J, Smith TL. Does olfactory function improve after endoscopic sinus surgery? Otolaryngol Head Neck Surg 2009; 140:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/37\">",
"      Mott AE, Cain WS, Lafreniere D, et al. Topical corticosteroid treatment of anosmia associated with nasal and sinus disease. Arch Otolaryngol Head Neck Surg 1997; 123:367.",
"     </a>",
"    </li>",
"    <li>",
"     Costanzo RM, Graziadei PP. Development and plasticity of the olfactory system. In: Neurobiology of Taste and Smell, Finger TE, Silver WL (Eds), John Wiley &amp; Sons, New York 1987. p.233.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/39\">",
"      Zusho H. Posttraumatic anosmia. Arch Otolaryngol 1982; 108:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/40\">",
"      London B, Nabet B, Fisher AR, et al. Predictors of prognosis in patients with olfactory disturbance. Ann Neurol 2008; 63:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/41\">",
"      DeVane CL, Ware MR, Lydiard RB. Pharmacokinetics, pharmacodynamics, and treatment issues of benzodiazepines: alprazolam, adinazolam, and clonazepam. Psychopharmacol Bull 1991; 27:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18455/abstract/42\">",
"      Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome. Am Fam Physician 2002; 65:615.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6846 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_1_18455=[""].join("\n");
var outline_f18_1_18455=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY AND PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chemosensory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Butanol threshold test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Whole mouth taste test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Spatial test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Flavor discrimination test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Somatosensory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nasal and paranasal sinus disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H290129756\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Parosmia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Dysgeusia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6846\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6846|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/15/10493\" title=\"table 1\">",
"      Diseases with impaired smell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/12/38092\" title=\"table 2\">",
"      Diseases with impaired taste",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/34/15916\" title=\"table 3\">",
"      Drugs chemicals affecting smell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/35/26174\" title=\"table 4\">",
"      Drugs chemicals impair taste",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13801?source=related_link\">",
"      Anatomy and etiology of taste and smell disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=related_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_1_18456="Clinical manifestations of seasonal influenza in adults";
var content_f18_1_18456=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of seasonal influenza in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/1/18456/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/1/18456/contributors\">",
"     Raphael Dolin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/1/18456/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/1/18456/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/1/18456/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/1/18456/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/1/18456/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza is an acute respiratory illness caused by influenza A or B viruses that occurs in outbreaks and epidemics worldwide, mainly during the winter season. Signs and symptoms of upper",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower respiratory tract involvement are present, along with indications of systemic illness such as fever, headache, myalgia, and weakness. Although acutely debilitating, influenza is a self-limited infection in the general population (uncomplicated influenza); however, it is associated with increased morbidity and mortality in certain high-risk populations (complicated influenza).",
"   </p>",
"   <p>",
"    The United States Centers for Disease Control and Prevention (CDC), in collaboration with the World Health Organization and its reporting network, tracks influenza virus isolates throughout the world to monitor disease activity and to predict the appropriate components for the annual influenza vaccine. Information, which is updated weekly, is available at",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/weekly/\">",
"     www.cdc.gov/flu/weekly/",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The clinical manifestations of seasonal influenza in adults will be reviewed here. The clinical manifestations of this infection in children are discussed separately. The epidemiology, diagnosis, prevention, and treatment of seasonal influenza infection, as well as the clinical manifestations of pandemic H1N1 influenza (\"swine influenza\") and avian influenza, are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=see_link\">",
"     \"Epidemiology of influenza\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5528?source=see_link\">",
"     \"Diagnosis of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2599?source=see_link\">",
"     \"Infection control measures to prevent seasonal influenza in healthcare settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=see_link\">",
"     \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22599?source=see_link\">",
"     \"Clinical manifestations and diagnosis of avian influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large amounts of influenza virus are often present in respiratory secretions of infected persons. As a result, infection can be transmitted through sneezing and coughing; influenza is thought to be transmitted primarily via large particle droplets (&gt;5 microns) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acquisition via large particle droplets requires close contact with an infected individual, since large particles do not remain suspended in the air and travel only short distances (~6 feet) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/3\">",
"     3",
"    </a>",
"    ]. Limited data suggest that small particle respiratory droplets, which become aerosolized and stay suspended in the air for long periods, also contain influenza virus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. However, the contribution of small particles to airborne transmission of influenza is unclear. Contact with surfaces that have been contaminated with respiratory droplets is another potential source of transmission, but is not a well established mode of transmission. Although the respiratory tract is presumed to be the primary site for the acquisition of infection, one study has suggested that transocular entry of influenza virus can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical incubation period for influenza is one to four days (average two days) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. The time between onset of illness among household contacts among whom transmission has occurred (termed the serial interval) is three to four days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/9\">",
"     9",
"    </a>",
"    ]. In a small influenza transmission study, the secondary attack rate was 25 percent among healthy individuals who socialized for 30 hours over a two-day period with volunteers who had been infected with influenza via intranasal drops [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection control measures to prevent the transmission of influenza in healthcare settings are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2599?source=see_link\">",
"     \"Infection control measures to prevent seasonal influenza in healthcare settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39276461\">",
"    <span class=\"h2\">",
"     Duration of shedding",
"    </span>",
"    &nbsp;&mdash;&nbsp;In otherwise healthy adults with influenza infection, viral shedding can be detected 24 to 48 hours before illness onset, but is generally at much lower titers than during the symptomatic period [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/11\">",
"     11",
"    </a>",
"    ]. In a review of 56 studies of 1280 healthy adults who were experimentally challenged with influenza virus, shedding of influenza virus increased sharply one-half to one day following exposure, peaked on the second day, and then rapidly declined [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/12\">",
"     12",
"    </a>",
"    ]. The average duration of shedding was 4.8 days (95% CI 4.3 to 5.3 days). Shedding ceased after six or seven days in most studies but occurred for up to 10 days in some. Studies of natural infection in healthy adults have shown similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/2,11,13-15\">",
"     2,11,13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Longer periods of shedding can occur in children, elderly adults [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/16\">",
"     16",
"    </a>",
"    ], patients with chronic illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], and immunocompromised hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. Among 147 inpatients &gt;16 years of age with H3N2 influenza A infection, systemic glucocorticoid use and comorbidities such as chronic lung disease or diabetes were associated with slower viral clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/17\">",
"     17",
"    </a>",
"    ]. Individuals who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    by symptom day four had an accelerated decrease in viral RNA concentration and clearance by one week. In a study that evaluated eight immunocompromised patients (seven with hematologic malignancy) who had shedding of influenza virus for &ge;2 weeks (median 30 days), lymphopenia was associated with prolonged shedding in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of healthy individuals with influenza infection, only 8 of 59 patients (14 percent) with detectable shedding of virus by reverse-transcriptase polymerase chain reaction (PCR) were asymptomatic, and peak viral titers were low in these cases, suggesting that shedding of virus from asymptomatic individuals may not contribute significantly to disease transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/14\">",
"     14",
"    </a>",
"    ]. In another study, asymptomatic viral shedding was detected by PCR in 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transmission of seasonal influenza in children and of 2009 pandemic H1N1 influenza A virus are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Transmission'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\", section on 'Transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     UNCOMPLICATED INFLUENZA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza characteristically begins with the abrupt onset of fever, headache, myalgia, and malaise [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/15,23-26\">",
"     15,23-26",
"    </a>",
"    ], following an incubation period of one to four days (average two days) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. These symptoms are accompanied by manifestations of respiratory tract illness, such as non-productive cough, sore throat, and nasal discharge. In some cases, the onset is so abrupt that patients can recall the precise time at which illness began. However, influenza infections also have a broad spectrum of other presentations that can range from afebrile respiratory illnesses similar to the common cold, to illnesses in which systemic signs and symptoms predominate with relatively little clinical indication of respiratory tract involvement.",
"   </p>",
"   <p>",
"    Physical findings generally are few in cases of uncomplicated influenza. The patient may appear hot and flushed; oropharyngeal abnormalities other than hyperemia are uncommon, even with complaints of severe sore throat. Mild cervical lymphadenopathy may be present and is more frequent in younger patients. Physical examination of the chest is generally unremarkable in uncomplicated influenza, although mild ventilatory defects and increased alveolar-capillary diffusion gradients have been described in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with uncomplicated influenza usually gradually improve over two to five days, although the illness may last for one week or more. Some patients have persistent symptoms of weakness or easy fatigability, referred to as postinfluenza asthenia, which last for several weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF INFLUENZA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonia is the most common complication of influenza, but other complications, especially involving muscle and the central nervous system, also occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major complication of influenza is pneumonia, which occurs most frequently in certain groups of patients with underlying chronic illnesses who are classified as high-risk (",
"    <a class=\"graphic graphic_table graphicRef72029 \" href=\"UTD.htm?32/50/33579\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of seasonal influenza in adults\", section on 'Definition of high risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The types of pneumonia that are encountered are categorized as primary viral pneumonia, secondary bacterial pneumonia, or a mixture of both.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Primary influenza pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary influenza pneumonia occurs when influenza virus infection directly involves the lung, typically producing a severe pneumonia. Clinical suspicion for primary influenza pneumonia should be raised when symptoms persist and increase instead of resolving in a patient with acute influenza. High fever, dyspnea, and even progression to cyanosis can be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary viral pneumonia is the most severe, although the least common, of the pneumonic complications of influenza. It has an apparent predilection for individuals who have elevated left atrial pressures, although it has also been described in patients with chronic pulmonary disorders, and rarely in apparently otherwise healthy young adults. In one report of an influenza A outbreak among adolescents attending a ski school, two patients were hospitalized with pneumonia and one died; polymerase chain reaction on lung tissue at autopsy was positive for influenza A [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H156881434\">",
"    <span class=\"h4\">",
"     Lung imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical radiographic manifestations of primary influenza pneumonia include bilateral reticular or reticulonodular opacities with or without superimposed consolidation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54985 \" href=\"UTD.htm?29/17/29969\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/30\">",
"     30",
"    </a>",
"    ]. Less frequently, radiographs show focal areas of consolidation, particularly in the lower lobes, without reticular or reticulonodular opacities. High-resolution computed tomography may show multifocal peribronchovascular or subpleural consolidation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ground glass opacities (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69600 \" href=\"UTD.htm?1/19/1329\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef78287 \" href=\"UTD.htm?30/63/31729\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Secondary bacterial pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary bacterial pneumonia is an important complication of influenza and contributes to approximately 25 percent of all influenza-associated deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hallmark of the clinical presentation in patients with secondary bacterial pneumonia is the exacerbation of fever and respiratory symptoms after initial improvement in the symptoms of acute influenza. Fever may abate for one or more days of acute influenza, but, instead of continuing to improve, the patient with secondary bacterial pneumonia relapses with higher fevers, cough, production of purulent sputum, and radiographic evidence of pulmonary infiltrates.",
"   </p>",
"   <p>",
"    Influenza virus affects tracheobronchial epithelium, directly leading to a decrease in the size of the cells and loss of cilia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/33\">",
"     33",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    In a mouse model of synergism between influenza virus and S. pneumoniae, the level of activity of neuraminidase correlated with increased adherence and invasion of S. pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/34\">",
"     34",
"    </a>",
"    ]. These events may predispose to bacterial infection of the lung (secondary bacterial pneumonia) and increased mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39276932\">",
"    <span class=\"h4\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common bacterial pathogen is Streptococcus pneumoniae (48 percent of cases in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/35\">",
"     35",
"    </a>",
"    ]. Staphylococcus aureus, which is an increasingly common cause of community-acquired pneumonia, is the second most common organism (19 percent), and Haemophilus influenzae pneumonia also may complicate influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. When the incidence of these pathogens was compared in an epidemic versus nonepidemic year for influenza, only S. aureus was significantly increased (19 versus 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39276939\">",
"    <span class=\"h5\">",
"     CA-MRSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has been identified in outbreaks of severe pneumonia with a high mortality rate in young previously healthy patients with influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Of 51 cases of community-acquired S. aureus pneumonia that followed influenza infections during the 2006 to 2007 influenza season in the United States, 79 percent of isolates with known susceptibilities were MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/37\">",
"     37",
"    </a>",
"    ]. The median age was 16 years, and 44 percent had no known significant medical history. Fifty-one percent of patients with S. aureus pneumonia for whom the outcome was known died a median of four days after symptom onset, although only 43 percent of patients with CA-MRSA were empirically treated with antimicrobial agents recommended for MRSA pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\", section on 'Community-associated methicillin-resistant Staphylococcus aureus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Mixed viral and bacterial pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is common for patients with influenza and a complicating pneumonia to have features of both viral and bacterial pneumonia. In these cases, patients may have either a gradual progression of illness or a transient improvement followed by worsening. Influenza virus and bacterial pathogens are usually present in the sputum. Pulmonary infiltrates, including areas of frank consolidation, may be noted by physical examination or chest radiograph.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Myositis and rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other important complications of influenza include myositis and rhabdomyolysis, which have been reported most frequently in children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Although myalgias are a prominent feature of most cases of influenza, true myositis is uncommon. The pathogenesis of the myositis is not well understood, although evidence for the presence of influenza virus in affected muscles has been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9879?source=see_link\">",
"     \"Viral myositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hallmark of acute myositis is extreme tenderness of the affected muscles, most commonly in the legs. In the most severe cases, swelling and bogginess of the muscles may be noted. Markedly elevated serum creatine phosphokinase concentrations are seen, and myoglobinuria with associated renal failure has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36745?source=see_link\">",
"     \"Muscle enzymes in the evaluation of neuromuscular diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Central nervous system involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system disease (CNS) may be associated with influenza, including encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/46-49\">",
"     46-49",
"    </a>",
"    ], transverse myelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/50\">",
"     50",
"    </a>",
"    ], aseptic meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/51\">",
"     51",
"    </a>",
"    ], and Guillain-Barr&eacute; syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/52\">",
"     52",
"    </a>",
"    ]. However, an etiologic relationship between influenza and these CNS diseases has not been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40038?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathogenesis of Guillain-Barr&eacute; syndrome in adults\", section on 'Other infections'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Neurologic'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cardiac complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several cardiac complications have been described in patients with influenza infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrocardiographic (ECG) changes are frequently noted in patients who develop influenza but are most often attributed to the underlying cardiac disease, rather than to direct involvement of the heart with influenza virus. Transient ECG changes have also been observed in patients with acute influenza infection who do not have preexisting cardiovascular disease. In a study of 30 previously healthy young adults with influenza infection, 53, 33, 27, and 23 percent had abnormal ECG findings on days 1, 4, 11, and 28 of presentation, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/53\">",
"       53",
"      </a>",
"      ]. No patients had elevated cardiac enzymes or abnormal echocardiograms.",
"     </li>",
"     <li>",
"      A large surveillance study examined the association between influenza and myocardial infarction (MI)-associated hospitalizations and deaths independent of cold weather effects; this was accomplished by evaluating populations in England and Wales as well as Hong Kong [",
"      <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/54\">",
"       54",
"      </a>",
"      ]. In both geographic regions, there were increases in MI-associated hospitalizations and deaths that corresponded to periods of influenza activity (a single winter peak in Great Britain; a large winter peak and a smaller summer peak in Hong Kong), suggesting a link between influenza and MI.",
"     </li>",
"     <li>",
"      A retrospective study examined the relationship of intense influenza outbreak periods to rates of ischemic heart disease (IHD)-related hospitalization and death among Maryland residents &ge;50 years of age over a seven-year period [",
"      <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/55\">",
"       55",
"      </a>",
"      ]. Rate ratios (RRs) for IHD-related hospitalization (RR 1.06), death (RR 1.16), and combined hospitalization for IHD and medically attended acute respiratory illness (RR 1.42) were significantly elevated during periods of intense influenza activity. Rate ratios for IHD-related hospitalizations increased with increasing age. Rate ratios of IHD-related hospitalization and combined hospitalization for IHD and medically attended acute respiratory illness also correlated positively with the proportion of circulating H3N2 influenza A viruses.",
"     </li>",
"     <li>",
"      In a series of patients with acute coronary syndrome, the risk of acute myocardial infarction was elevated during days one through three after acute respiratory infection (incidence ratio 4.19, 95% CI 3.18-5.53) and tapered over time. The effect was greatest among those &ge;80 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/56\">",
"       56",
"      </a>",
"      ]. The presence of at least one indicator of influenza infection (acute respiratory infection within four weeks of peak influenza activity, coding for influenza-like illness, and unvaccinated status) was associated with a higher incidence ratio for acute myocardial infarction.",
"     </li>",
"     <li>",
"      Myocarditis and pericarditis have generally been considered rare complications of influenza [",
"      <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/57\">",
"       57",
"      </a>",
"      ]. However, in a study of fatal cases of influenza B infection, myocarditis was found commonly at autopsy; myocardial injury was identified in 20 of 29 patients (69 percent) who had cardiac specimens available for histology and 10 of these had unequivocal myocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/58\">",
"       58",
"      </a>",
"      ]. No viral antigens were detected in the myocardium by immunohistochemistry, suggesting that myocardial injury is not a direct effect of the virus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1049852288\">",
"    <span class=\"h2\">",
"     Toxic shock syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic shock syndrome associated with Staphylococcus aureus infection and acute influenza has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Most reported cases have been due to influenza B [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18456/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=see_link\">",
"       \"Patient information: Flu (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=see_link\">",
"       \"Patient information: Influenza symptoms and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1421184\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Influenza is an acute respiratory illness caused by influenza A or B viruses; it often occurs in outbreaks and epidemics worldwide, mainly during the winter season. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Large amounts of influenza virus are often present in respiratory secretions of infected persons. As a result, infection can be transmitted through sneezing and coughing via large particle droplets. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The average duration of influenza virus shedding in immunocompetent patients is five days. Shedding typically ceases after six or seven days but may continue for up to 10 days or more, particularly in children, elderly adults, patients with chronic illnesses, and immunocompromised hosts. (See",
"      <a class=\"local\" href=\"#H39276461\">",
"       'Duration of shedding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Influenza characteristically begins with the abrupt onset of fever, headache, myalgia, and malaise after an incubation period of one to four days (average two days). These symptoms and signs are accompanied by manifestations of respiratory tract illness, such as non-productive cough, sore throat, and nasal discharge. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Uncomplicated influenza'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major complication of influenza is pneumonia, which occurs most frequently in certain groups of patients with underlying chronic illnesses who are classified as high-risk for this infection (",
"      <a class=\"graphic graphic_table graphicRef72029 \" href=\"UTD.htm?32/50/33579\">",
"       table 1",
"      </a>",
"      ). The types of pneumonia that are encountered are categorized as primary viral pneumonia, secondary bacterial pneumonia, or a mixture of both. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Central nervous system disease may be associated with influenza; manifestations may include encephalitis, transverse myelitis, aseptic meningitis, and Guillain-Barr&eacute; syndrome. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Central nervous system involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other complications of influenza include myositis, rhabdomyolysis, myocarditis, pericarditis, and toxic shock syndrome. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Myositis and rhabdomyolysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Cardiac complications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1049852288\">",
"       'Toxic shock syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/1\">",
"      Mubareka S, Lowen AC, Steel J, et al. Transmission of influenza virus via aerosols and fomites in the guinea pig model. J Infect Dis 2009; 199:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/2\">",
"      Brankston G, Gitterman L, Hirji Z, et al. Transmission of influenza A in human beings. Lancet Infect Dis 2007; 7:257.",
"     </a>",
"    </li>",
"    <li>",
"     US Centers for Disease Control and Prevention. Interim guidance on the use of influenza antiviral agents during the 2010-2011 influenza season file://www.cdc.ov/flu/professionals/antivirals/guidance/summary.htm (Accessed on December 28, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/4\">",
"      Blachere FM, Lindsley WG, Pearce TA, et al. Measurement of airborne influenza virus in a hospital emergency department. Clin Infect Dis 2009; 48:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/5\">",
"      Wong BC, Lee N, Li Y, et al. Possible role of aerosol transmission in a hospital outbreak of influenza. Clin Infect Dis 2010; 51:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/6\">",
"      Noti JD, Lindsley WG, Blachere FM, et al. Detection of infectious influenza virus in cough aerosols generated in a simulated patient examination room. Clin Infect Dis 2012; 54:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/7\">",
"      Bischoff WE, Reid T, Russell GB, Peters TR. Transocular entry of seasonal influenza-attenuated virus aerosols and the efficacy of n95 respirators, surgical masks, and eye protection in humans. J Infect Dis 2011; 204:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/8\">",
"      Cox NJ, Subbarao K. Influenza. Lancet 1999; 354:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/9\">",
"      Cowling BJ, Chan KH, Fang VJ, et al. Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med 2010; 362:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/10\">",
"      Killingley B, Enstone JE, Greatorex J, et al. Use of a human influenza challenge model to assess person-to-person transmission: proof-of-concept study. J Infect Dis 2012; 205:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/11\">",
"      Bell DM, World Health Organization Writing Group. Non-pharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis 2006; 12:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/12\">",
"      Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008; 167:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/13\">",
"      Aoki FY, Boivin G. Influenza virus shedding: excretion patterns and effects of antiviral treatment. J Clin Virol 2009; 44:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/14\">",
"      Lau LL, Cowling BJ, Fang VJ, et al. Viral shedding and clinical illness in naturally acquired influenza virus infections. J Infect Dis 2010; 201:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/15\">",
"      Loeb M, Singh PK, Fox J, et al. Longitudinal study of influenza molecular viral shedding in Hutterite communities. J Infect Dis 2012; 206:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/16\">",
"      Leekha S, Zitterkopf NL, Espy MJ, et al. Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol 2007; 28:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/17\">",
"      Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/18\">",
"      Klimov AI, Rocha E, Hayden FG, et al. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995; 172:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/19\">",
"      Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998; 26:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/20\">",
"      Boivin G, Goyette N, Bernatchez H. Prolonged excretion of amantadine-resistant influenza a virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin Infect Dis 2002; 34:E23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/21\">",
"      Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/22\">",
"      Gooskens J, Jonges M, Claas EC, et al. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis 2009; 199:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/23\">",
"      Nicholson KG. Clinical features of influenza. Semin Respir Infect 1992; 7:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/24\">",
"      Dolin R. Influenza: current concepts. Am Fam Physician 1976; 14:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/25\">",
"      KILBOURNE ED, LOGE JP. Influenza A prime: a clinical study of an epidemic caused by a new strain of virus. Ann Intern Med 1950; 33:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/26\">",
"      Stuart-Harris, CH. Twenty years of influenza epidemics. Am Rev Respir Dis 1961; 83:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/27\">",
"      Hall WJ, Douglas RG Jr, Hyde RW, et al. Pulmonary mechanics after uncomplicated influenza A infection. Am Rev Respir Dis 1976; 113:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/28\">",
"      MARTIN CM, KUNIN CM, GOTTLIEB LS, et al. Asian influenza A in Boston, 1957-1958. I. Observations in thirty-two influenza-associated fatal cases. AMA Arch Intern Med 1959; 103:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/29\">",
"      Lyytik&auml;inen O, Hoffmann E, Timm H, et al. Influenza A outbreak among adolescents in a ski hostel. Eur J Clin Microbiol Infect Dis 1998; 17:128.",
"     </a>",
"    </li>",
"    <li>",
"     Muller NL, Franquet T, Lee KS, Silva CIS. Viruses, Mycoplasma, and Chlamydia. In: Imaging of Pulmonary Infections, Lippincott Williams and Wilkins, Philadelphia 2007. p.94.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/31\">",
"      Kim EA, Lee KS, Primack SL, et al. Viral pneumonias in adults: radiologic and pathologic findings. Radiographics 2002; 22 Spec No:S137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/32\">",
"      Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine 1999; 17 Suppl 1:S3.",
"     </a>",
"    </li>",
"    <li>",
"     Treanor JJ. Influenza virus. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.2060.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/34\">",
"      Peltola VT, Murti KG, McCullers JA. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis 2005; 192:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/35\">",
"      Schwarzmann SW, Adler JL, Sullivan RJ Jr, Marine WM. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. Arch Intern Med 1971; 127:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/36\">",
"      Bisno AL, Griffin JP, Van Epps KA, et al. Pneumonia and Hong Kong influenza: a prospective study of the 1968-1969 epidemic. Am J Med Sci 1971; 261:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/37\">",
"      Kallen AJ, Brunkard J, Moore Z, et al. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med 2009; 53:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/38\">",
"      Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/39\">",
"      Centers for Disease Control and Prevention (CDC). Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza--Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007; 56:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/40\">",
"      Dietzman DE, Schaller JG, Ray CG, Reed ME. Acute myositis associated with influenza B infection. Pediatrics 1976; 57:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/41\">",
"      Dell KM, Schulman SL. Rhabdomyolysis and acute renal failure in a child with influenza A infection. Pediatr Nephrol 1997; 11:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/42\">",
"      Cunningham E, Kohli R, Venuto RC. Influenza-associated myoglobinuric renal failure. JAMA 1979; 242:2428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/43\">",
"      Gamboa ET, Eastwood AB, Hays AP, et al. Isolation of influenza virus from muscle in myoglobinuric polymyositis. Neurology 1979; 29:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/44\">",
"      Abe M, Higuchi T, Okada K, et al. Clinical study of influenza-associated rhabdomyolysis with acute renal failure. Clin Nephrol 2006; 66:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/45\">",
"      Naderi AS, Palmer BF. Rhabdomyolysis and acute renal failure associated with influenza virus type B infection. Am J Med Sci 2006; 332:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/46\">",
"      Bayer WH. Influenza B encephalitis. West J Med 1987; 147:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/47\">",
"      Fujimoto S, Kobayashi M, Uemura O, et al. PCR on cerebrospinal fluid to show influenza-associated acute encephalopathy or encephalitis. Lancet 1998; 352:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/48\">",
"      Steininger C, Popow-Kraupp T, Laferl H, et al. Acute encephalopathy associated with influenza A virus infection. Clin Infect Dis 2003; 36:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/49\">",
"      Hjalmarsson A, Blomqvist P, Brytting M, et al. Encephalitis after influenza in Sweden 1987-1998: a rare complication of a common infection. Eur Neurol 2009; 61:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/50\">",
"      Salonen O, Koshkiniemi M, Saari A, et al. Myelitis associated with influenza A virus infection. J Neurovirol 1997; 3:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/51\">",
"      Rotbart HA. Viral meningitis. Semin Neurol 2000; 20:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/52\">",
"      Sivadon-Tardy V, Orlikowski D, Porcher R, et al. Guillain-Barr&eacute; syndrome and influenza virus infection. Clin Infect Dis 2009; 48:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/53\">",
"      Ison MG, Campbell V, Rembold C, et al. Cardiac findings during uncomplicated acute influenza in ambulatory adults. Clin Infect Dis 2005; 40:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/54\">",
"      Warren-Gash C, Bhaskaran K, Hayward A, et al. Circulating influenza virus, climatic factors, and acute myocardial infarction: a time series study in England and Wales and Hong Kong. J Infect Dis 2011; 203:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/55\">",
"      Lichenstein R, Magder LS, King RE, King JC Jr. The relationship between influenza outbreaks and acute ischemic heart disease in Maryland residents over a 7-year period. J Infect Dis 2012; 206:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/56\">",
"      Warren-Gash C, Hayward AC, Hemingway H, et al. Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. J Infect Dis 2012; 206:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/57\">",
"      Mamas MA, Fraser D, Neyses L. Cardiovascular manifestations associated with influenza virus infection. Int J Cardiol 2008; 130:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/58\">",
"      Paddock CD, Liu L, Denison AM, et al. Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. J Infect Dis 2012; 205:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/59\">",
"      MacDonald KL, Osterholm MT, Hedberg CW, et al. Toxic shock syndrome. A newly recognized complication of influenza and influenzalike illness. JAMA 1987; 257:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18456/abstract/60\">",
"      Tolan RW Jr. Toxic shock syndrome complicating influenza A in a child: case report and review. Clin Infect Dis 1993; 17:43.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7004 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-07BE0D3610-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_1_18456=[""].join("\n");
var outline_f18_1_18456=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1421184\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39276461\">",
"      Duration of shedding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      UNCOMPLICATED INFLUENZA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COMPLICATIONS OF INFLUENZA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Primary influenza pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H156881434\">",
"      Lung imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Secondary bacterial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H39276932\">",
"      Microbiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H39276939\">",
"      - CA-MRSA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Mixed viral and bacterial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Myositis and rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Central nervous system involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cardiac complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1049852288\">",
"      Toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1421184\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7004\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7004|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/17/29969\" title=\"diagnostic image 1\">",
"      Influenza pneumonia CXR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/19/1329\" title=\"diagnostic image 2\">",
"      Influenza pneumonia CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7004|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/63/31729\" title=\"picture 1\">",
"      Severe influenza pneumonia CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7004|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/50/33579\" title=\"table 1\">",
"      Groups at high risk for influenza complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=related_link\">",
"      Clinical features and diagnosis of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22599?source=related_link\">",
"      Clinical manifestations and diagnosis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=related_link\">",
"      Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5528?source=related_link\">",
"      Diagnosis of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=related_link\">",
"      Epidemiology of influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2599?source=related_link\">",
"      Infection control measures to prevent seasonal influenza in healthcare settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36745?source=related_link\">",
"      Muscle enzymes in the evaluation of neuromuscular diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40038?source=related_link\">",
"      Pathogenesis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=related_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9879?source=related_link\">",
"      Viral myositis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_1_18457="Fetal adenoca lung low power";
var content_f18_1_18457=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fetal adenocarcinoma of the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph showing the typical appearance of fetal adenocarcinoma. The tumor cells are arranged in well-formed acini and have abundant clear cytoplasm due to the presence of intracytoplasmic glycogen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_1_18457=[""].join("\n");
var outline_f18_1_18457=null;
var title_f18_1_18458="Induction and maintenance of immunosuppressive therapy in cardiac transplantation";
var content_f18_1_18458=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Induction and maintenance of immunosuppressive therapy in cardiac transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/1/18458/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/1/18458/contributors\">",
"     Michael X Pham, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/1/18458/contributors\">",
"     Hannah A Valantine, MD, MRCP, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/1/18458/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/1/18458/contributors\">",
"     Sharon A Hunt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/1/18458/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/1/18458/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/1/18458/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of immunosuppression is to prevent or treat cardiac allograft rejection while minimizing both drug toxicities as well as the major sequelae of immune suppression, namely infection and malignancy. Most clinically used immunosuppressive regimens consist of a combination of several agents used concurrently and follow several general principles.",
"   </p>",
"   <p>",
"    Immunosuppressive regimens can be classified as induction, maintenance, or anti-rejection. Induction regimens provide intense early post-operative immune suppression while maintenance regimens are used throughout the patient's life to prevent both acute and chronic rejection. This topic will review the induction and maintenance immunosuppressive regimens used in heart transplantation. The management of acute allograft rejection and the diagnosis and allograft vasculopathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14441?source=see_link\">",
"     \"Acute cardiac allograft rejection: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=see_link\">",
"     \"Prevention and treatment of cardiac allograft vasculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three general principles govern induction and maintenance immunosuppressive therapy regimens. The first principle is that immune reactivity and tendency toward graft rejection are highest early (within the first three to six months) after graft implantation and decrease with time. Thus, most regimens employ the highest intensity of immunosuppression immediately after surgery and decrease the intensity of therapy over the first year, eventually settling on the lowest maintenance levels of immunosuppression that are compatible with preventing graft rejection while minimizing drug toxicities. The second principle is to use low doses of several drugs with non-overlapping toxicities in preference over higher (and more toxic) doses of fewer drugs whenever feasible. The third principle is to avoid over-immunosuppression, because it leads to a myriad of undesirable effects including susceptibility to infection and malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDUCTION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 50 percent of heart transplant programs currently employ a strategy of augmented immunosuppression, or",
"    <strong>",
"     induction",
"    </strong>",
"    therapy, during the early post-operative period [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/1\">",
"     1",
"    </a>",
"    ]. The goal of induction therapy is to provide intense immunosuppression when the risk of allograft rejection is highest. From a clinical perspective, the main advantages of induction therapy are to allow delayed initiation of nephrotoxic immunosuppressive drugs in patients with compromised renal function prior to or following surgery and to provide some flexibility with respect to early glucocorticoid weaning or use of glucocorticoid-sparing baseline regimens after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several anti-lymphocyte antibodies that target specific epitopes on the surface of both B and T cells have been used as part of induction therapy. However, the overall strategy of universal induction therapy and the optimal drugs to achieve a state of early intense immunosuppression remain controversial. The decreased early rejection observed with induction therapy may be negated by an increase in late rejection after induction therapy is completed and by the potential for increased rates of infection and malignancy associated with such therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/5-11\">",
"     5-11",
"    </a>",
"    ]. However, patients at highest risk for fatal rejection, including younger patients, African American patients, patients with a high number of HLA mismatches, and patients supported on ventricular assist devices with high levels of pre-formed antibodies, may derive a benefit from induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Interleukin-2 receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of interleukin-2 (IL-2) receptor antagonists for induction therapy has increased, and these drugs are now used in 27 percent of patients undergoing heart transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/1\">",
"     1",
"    </a>",
"    ]. The currently available agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"     Basiliximab",
"    </a>",
"    (Simulect), is a monoclonal antibody that selectively binds to the IL-2 receptor of T-lymphocytes, block binding of IL-2 to the receptor complex, and exhibiting its immunosuppressive effects by inhibiting IL-2 mediated T-lymphocyte proliferation. Daclizumab (Zenapax) was discontinued by the manufacturer in 2009 due to diminishing market demand. Compared to OKT3 and anti-thymocyte antibodies, this class of drugs has a significantly lower incidence of drug-related adverse reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"     Basiliximab",
"    </a>",
"    was studied in a pilot multicenter, placebo-controlled randomized study of 56",
"    <strong>",
"     de novo",
"    </strong>",
"    heart transplant recipients designed to assess the safety, tolerability, and pharmacokinetics of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients were randomized to two doses of either basiliximab or placebo in addition to a background immunosuppressive regimen that included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and glucocorticoids. There were no significant differences between treatment groups with respect to drug-related adverse events or infections. At six months, a non-statistically significant trend toward a decrease in the mean number of days to a first biopsy-proven acute rejection episode of ISHLT Grade &ge; 2R or a rejection episode with hemodynamic compromise was observed in the basiliximab group compared to placebo (74 versus 41 days).",
"   </p>",
"   <p>",
"    Daclizumab was studied in a large, multicenter, double-blind study in which patients were randomized to five doses of daclizumab within two weeks apart or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/16\">",
"     16",
"    </a>",
"    ]. All patients received cyclosporine, mycophenolate mofetil, and glucocorticoids as part of baseline immunosuppression. At six months, the composite incidence of biopsy-detected moderate or severe cellular rejection, hemodynamically significant graft dysfunction, death, re-transplantation, or loss to follow-up was significantly lower in the daclizumab group compared to placebo (36 versus 48 percent). The difference in endpoint was due primarily to a decreased incidence of biopsy-proven rejection in the daclizumab group (41 versus 26 percent). There was no significant difference in the incidence of opportunistic infection or cancer at one year. However, among patients receiving daclizumab induction, there was an increased risk of fatal infection when T-cell cytolytic therapy was concomitantly used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Polyclonal anti-thymocyte antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyclonal antibodies are derived by immunization of horses (ATGAM&reg;, also called lymphocyte immune globulin) or rabbits (Thymoglobulin&reg;) with human thymocytes. These agents combined are currently employed in 23 percent of heart transplant recipients based upon the most recent international transplant registry data [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These preparations contain antibodies directed against a wide variety of human T-cell antigens and cause rapid depletion of T-lymphocytes by inducing complement-mediated cytolysis and cell-mediated opsonization in the spleen and liver. There are no head-to-head comparison trials of ATGAM&reg; and Thymoglobulin&reg; in heart transplantation, but data from the kidney transplant literature suggests that Thymoglobulin&reg; may result in a lower incidence of both short and long-term acute rejection compared to ATGAM&reg;, possibly because of more profound and durable lymphopenia after Thymoglobulin&reg; administration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32649?source=see_link\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major acute side effects associated with this class of drugs include a serum sickness reaction characterized by fevers, chills, tachycardia, hypertension or hypotension, myalgias, and rash. The reaction is typically noticed during the first or second drug infusion and can be treated by temporarily stopping the drug infusion and restarting at a lower infusion rate. Pre-medication with intravenous glucocorticoids, antihistamines, antipyretics, and H2 blockers can prevent or reduce the severity of symptoms. Dose-dependent leukopenia (30 to 50 percent) and thrombocytopenia (30 to 40 percent) have also been observed and typically respond to dose reduction or drug discontinuation for severe cases (WBC &lt;2,000",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    or platelet count &lt;50,000",
"    <span class=\"nowrap\">",
"     cells/mm3).",
"    </span>",
"    These agents do not induce a host antibody response to horse or rabbit sera and can be re-used for the treatment of allograft rejection. Long-term side effects include a pre-disposition to opportunistic infections, particularly with cytomegalovirus and a possible increase in the incidence and aggressiveness of post-transplant malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/11,19,20\">",
"     11,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Muromonab-CD3 (OKT3)",
"    </span>",
"    &nbsp;&mdash;&nbsp;OKT3 is a murine monoclonal antibody that binds to the T cell receptor-CD3 complex on the surface of circulating T cells. It exerts its immunosuppressive effects via a variety of mechanisms, including rapid T cell depletion from the peripheral circulation as a result of opsonization in the liver and spleen, and modulation of the T cell receptor-CD3 antigen recognition complex, thereby blocking the immunologic function of these cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OKT3 administration is associated with a number of important acute and long-term side effects. The first or second drug dose is typically associated with a",
"    <strong>",
"     cytokine release syndrome",
"    </strong>",
"    characterized by fevers, rigors, nausea, vomiting, diarrhea, hypotension, chest pain, dyspnea or wheezing, arthralgias, and myalgias. This syndrome is caused by initial activation of T cells and release of multiple cytokines. It can be attenuated by pre-medication with intravenous steroids, antihistamines, antipyretics, and H2-blockers. Rare life-threatening complications have included pulmonary edema, aseptic meningitis, and encephalopathy. Long-term adverse reactions include an increased risk of life-threatening opportunistic infections, particularly with cytomegalovirus and post-transplant lymphoproliferative disorders. Finally, prolonged use of OKT3 can elicit a host anti-mouse antibody response that can blunt future drug efficacy and increase the risk of antibody-mediated rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to these adverse effects and the availability of alternate agents, the use of OKT3 as induction therapy in heart transplantation has significantly declined between 1997 and 2007 and is now used in less than 1 percent of heart transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    (Campath-1H) is a humanized rat monoclonal antibody that targets the CD52 antigen expressed on both T and B cells. This powerful cytolytic agent produces a profound lymphopenia that lasts for approximately six months and that may persist for up to three years in some individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/26\">",
"     26",
"    </a>",
"    ]. The agent was originally developed to treat chronic lymphocytic leukemia but has also been used as induction therapy in solid organ transplantation, mostly in kidney transplant recipients, where it has permitted use of lower intensity maintenance immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/27\">",
"     27",
"    </a>",
"    ]. Use of this drug is under active investigation in heart transplantation, and early experience suggests that Campath may decrease the incidence of early (&lt;12 months) acute cellular rejection while allowing the use of lower intensity maintenance immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MAINTENANCE IMMUNOSUPPRESSIVE REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strategies and drugs used for immune suppression have advanced considerably since the first heart transplant was performed in 1967. Beginning with the introduction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in 1983, significant advances have been made in moving from drugs that provide broad and non-specific immunosuppression to newer agents that provide more targeted immunosuppression through selective inhibition of lymphocyte activation and proliferation. This selectivity has resulted in a marked increase in patient survival due to a decrease in the incidence of both life-threatening opportunistic infections and rejection episodes. Most maintenance immunosuppressive protocols employ a three-drug regimen consisting of a calcineurin-inhibitor (cyclosporine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ), an antimetabolite agent (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil or less commonly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ), and tapering doses of glucocorticoids over the first year post-transplantation. The commonly used drugs in heart transplantation and their toxicities are outlined (",
"    <a class=\"graphic graphic_table graphicRef50962 \" href=\"UTD.htm?22/55/23421\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Calcineurin-inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the introduction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in the early 1980s, the calcineurin inhibitors have remained the cornerstone of maintenance immunosuppressive therapy in heart and other solid organ transplantation. These drugs exert their immunosuppressive effects by inhibiting calcineurin, which is normally responsible for the transcription of IL-2 and several other cytokines, including TNF alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma. The end result is blunting of T-lymphocyte activation and proliferation in response to alloantigens. The two available calcineurin inhibitors, cyclosporine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , form complexes with different intracellular binding proteins, and these drug-protein complexes subsequently bind to and inhibit calcineurin. The drugs differ with respect to both efficacy and side effect profile. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    (Prograf), previously known as FK-506, is a macrolide compound derived from the fungus Streptomyces tsukubaensis. It binds to a cytoplasmic protein called FK binding protein and inhibits calcineurin via a similar pathway to that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . The FDA originally approved the drug in 1995 for use in liver transplantation and later approved it for use in kidney (1997) and heart (2006) transplantation. In recent years, the use of tacrolimus in heart transplantation has increased, and it is currently the most widely used calcineurin-inhibitor.",
"   </p>",
"   <p>",
"    Multiple single-center and multi-center randomized comparisons between de novo use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    after heart transplantation have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/29-35\">",
"     29-35",
"    </a>",
"    ]. As a whole, these trials have shown similar patient survival and a more favorable side effect profile with tacrolimus. For example, the calcineurin-inhibitor associated metabolic derangements appear to be significantly attenuated with tacrolimus use. Patients on tacrolimus, compared to cyclosporine, consistently had less hypertension and less hyperlipidemia. Two studies showed modest benefits with respect to renal function in the tacrolimus group [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], while one study demonstrated a higher incidence of post-transplant diabetes with tacrolimus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/29\">",
"     29",
"    </a>",
"    ]. With respect to efficacy, a few studies showed a decreased incidence of biopsy-proven acute rejection or drug-treated acute rejection in the tacrolimus treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/29,36\">",
"     29,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest head-to-head comparison of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , 314 de novo heart transplant recipients were randomized to either tacrolimus or microemulsion-based cyclosporine in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/29\">",
"     29",
"    </a>",
"    ]. All patients underwent induction therapy with either thymoglobulin or OKT3. Over 18 months of follow-up, patient survival was similar in both groups. However, patients in the tacrolimus group had a lower incidence of biopsy-proven moderate or severe acute cellular rejection at six months compared to the cyclosporine group (28 versus 42 percent, p = 0.013). Significant differences were also detected between the tacrolimus and cyclosporine group with respect to new onset diabetes mellitus (20 percent versus 11 percent), hypertension (66 versus 78 percent), and dyslipidemia (29 versus 40 percent). The incidence and patterns of infection, as well as renal function, were similar in the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Dosing and therapeutic drug monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    is available as oral capsules and as an injectable solution. The drug is typically given orally. When intravenous administration is required, approximately one-third of the daily oral dose should be given as a continuous infusion over 24 hours. Drug dosing is titrated to achieve therapeutic 12-hour trough levels. In general, target levels are typically highest in the first six months (10 to 15",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    and lower thereafter (5 to 10",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Major toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is associated with less hypertension and dyslipidemia. However, an increased frequency of new-onset diabetes mellitus has been observed in patients on tacrolimus compared with cyclosporine (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is a peptide derived from the fungus Tolypocladium inflatum that has powerful immunosuppressive properties. It binds to the cytoplasmic protein cyclophilin to inhibit calcineurin. The drug is available in several formulations. The older oil-based formulation called Sandimmune was characterized by variable and incomplete absorption. The newer modified formulations, including Gengraf and Neoral, are microemulsion formulations that result in improved and more reproducible drug absorption. In a randomized, multi-center, double-blind comparison of the oil-based (Sandimmune) versus the microemulsion (Neoral) cyclosporine formulations in de novo heart transplant recipients, the use of Neoral was associated with fewer rejection episodes requiring antilymphocyte antibody therapy compared to Sandimmune at 24 months (7 versus 18 percent, p = 0.002). Graft and patient survival were identical in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to their improved pharmacokinetic profile, the microemulsion preparations are generally preferred over the oil-based formulation. The two formulations are not considered bioequivalent, and patients should not be routinely switched from one to the other without close monitoring of drug levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Dosing and therapeutic drug monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is available as oil-based or microemulsion capsules, as an oral microemulsion solution, and as a concentrate for injection. When given intravenously, approximately one third of the daily oral dose should be given as two infusions 12 hours apart or as a continuous infusion over 24 hours. The drug is typically titrated to achieve therapeutic 12-hour trough levels. In general, cyclosporine levels are kept highest in the first year post-transplantation (200 to 350",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    and lowered in subsequent periods (100 to 200",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"    However, target drug levels should be individualized according to a patient's risk of rejection, renal function, and susceptibility to drug toxicities and infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Major toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major toxicities of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    include renal insufficiency, hypertension, dyslipidemia, hypokalemia and hypomagnesemia, and neurotoxicity (",
"    <a class=\"graphic graphic_table graphicRef50962 \" href=\"UTD.htm?22/55/23421\">",
"     table 1",
"    </a>",
"    ). Gingival hyperplasia and hirsutism are two additional side effects that are unique to cyclosporine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ANTIMETABOLITES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antimetabolites, or antiproliferative agents, interfere with the synthesis of nucleic acids and exert their immunosuppressive effects by inhibiting the proliferation of both T and B lymphocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    (Imuran) is a prodrug that is first rapidly hydrolyzed in the blood to its active form, 6-mercaptopurine, and subsequently converted to a purine analogue, thio-inosine-monophosphate. This antimetabolite is incorporated into DNA and inhibits further nucleotide synthesis, thereby preventing mitosis and proliferation of rapidly dividing cells such as activated T and B lymphocytes. This drug is typically used as an adjunctive immunosuppressive agent with either glucocorticoids or, more commonly, in conjunction with a calcineurin inhibitor. The major side effects include dose-dependent myelosuppression, particularly leukopenia. Azathioprine should be temporarily withheld if the white cell count falls below",
"    <span class=\"nowrap\">",
"     3000/mm2",
"    </span>",
"    or drops by 50 percent compared to the previous value. Other potentially serious side effects include hepatotoxicity and pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF, Cellcept) has replaced",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    as the preferred antimetabolite agent in recent years. It is also a prodrug that is rapidly hydrolyzed to its active form, mycophenolic acid (MPA). MPA is a reversible inhibitor of inosine monophosphate dehydrogenase, a critical enzyme for the de-novo synthesis of guanine nucleotides. Lymphocytes lack a key enzyme in the guanine salvage pathway and are dependent upon the de novo pathway for the production of purines necessary for RNA and DNA synthesis. Therefore both T- and B-lymphocytes proliferation is selectively inhibited.",
"   </p>",
"   <p>",
"    In a multi-center, active-controlled, randomized trial,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil was compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    when used in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and corticosteroids in 650 de novo heart transplant recipients. Because an intravenous form of the study drug (mycophenolate mofetil) was not available at the time of the trial, 11 percent of the patients withdrew before receiving the drug. Survival and rejection were similar in both groups when analyzed in an intention-to-treatment manner. However, among treated patients, mycophenolate mofetil was associated with a significant reduction in both mortality (6 versus 11 percent, p = 0.031) and in the incidence of treatable rejection (66 versus 74 percent, p = 0.026) at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Dosing and therapeutic drug monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil is available as an oral tablet or capsule and as a powder for injection. The intravenous solution is given at the same oral dose as a two hour infusion every 12 hours. The drug is typically administered at a starting dose of 1000 to 1500 mg twice daily and subsequently decreased as needed in response to leukopenia and gastrointestinal intolerance. While drug monitoring is not routinely performed, some centers target MPA trough levels between 2 to 5",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Major toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil is not nephrotoxic and causes less bone marrow suppression compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . The main side effects include dose related leukopenia and gastrointestinal toxicities such as nausea, gastritis, and diarrhea. A possible association between mycophenolate mofetil and Progressive Multifocal Leukoencephalopathy (PML) has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Mycophenolate sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    sodium (EC-MPS) is an enteric coated, delayed release salt of mycophenolic acid developed to improve the upper gastrointestinal tolerability of mycophenolate. Mycophenolic sodium is available in 180 mg and 360 mg enteric coated tablets. Because of this coating, the tablet should",
"    <strong>",
"     NOT",
"    </strong>",
"    be crushed. The following conversions between mycophenolate mofetil (MMF) and mycophenolate sodium should provide equimolar amounts of MPA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      1000 mg MMF = 720 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      sodium",
"     </li>",
"     <li>",
"      1500 mg MMF = 1080 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      sodium",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Single and multi-studies in de novo heart transplant recipients have shown that EC-MPS is therapeutically similar to MMF with respect to prevention of both biopsy-proven and treated acute rejection episodes, graft loss, or death. However, significantly fewer patients in the EC-MPS group required dose reductions during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROLIFERATION SIGNAL INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A new class of drugs known as proliferation signal inhibitors, or mammalian target of rapamycin (mTOR) inhibitors, has been used in selected patients with renal insufficiency, cardiac allograft vasculopathy, or malignancies in an attempt to reverse or slow progression of these conditions. However, the high incidence of drug-related adverse effects, including delayed sternal wound healing after transplantation, may limit the widespread use of these agents as de novo therapy following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two drugs in this class,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    , have similar mechanisms of action. They are structurally similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    and also bind to the FK binding protein. However, they exert their immunosuppressive effects via a calcineurin-independent mechanism. The drug-immunophilin complex inhibits a protein kinase in the cytoplasm called mammalian target of rapamycin (mTOR). mTOR is involved in the transduction signals from the IL-2 receptor to the nucleus, causing cell cycle arrest at the G1 to S phase. The consequence of mTOR inhibition is inhibition of both T- and B-cell proliferation in response to cytokine signals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Sirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    (Rapamune) is a macrolide antibiotic derived from the fungus Streptomyces hygroscopicus. The efficacy of sirolimus as an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    was evaluated in a prospective, open-label, randomized trial of 136 de novo heart transplant recipients. Patients were randomized 2:1 to receive one of two sirolimus doses (3 or 5 mg) or to azathioprine. Sirolimus doses were subsequently adjusted in both groups to achieve similar target blood levels. All patients received concurrent immunosuppression with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and glucocorticoids. Compared to azathioprine, the proportion of patients with a biopsy-proven moderate to severe acute cellular rejection episode at six months was lower in both the 3",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (32 versus 57 percent, p = 0.027) and 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    sirolimus groups (33 versus 57 percent, p = 0.013). Additionally, the progression of cardiac allograft vasculopathy, as defined by intravascular ultrasound, was significantly reduced in the sirolimus group at both six months and two years. Patient survival at 12 months was comparable among groups [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Dosing and therapeutic drug monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    is available in a liquid or tablet formulation. When used in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -modified capsules (Gengraf or Neoral), sirolimus should be given four hours after cyclosporine administration to minimize the pharmacokinetic interaction between the two drugs. Dosing is typically adjusted to achieve serum trough levels of 5 to 10",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    However, target ranges may vary depending upon the assay (immunoassay versus chromatographic) used, and clinicians should be familiar with the reference range for the assay used at their institutions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Major toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    has no inherent nephrotoxic effects but can potentiate the efficacy and nephrotoxic effects of the calcineurin inhibitors. Therefore, when these agents are used together, the dosage of the calcineurin inhibitor should be reduced by approximately 25 percent. The most common drug-related toxicities include hyperlipidemia, oral ulcerations, lower extremity edema, and bone marrow suppression with leukopenia, thrombocytopenia, and anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/44\">",
"     44",
"    </a>",
"    ]. Post-surgical wound healing complications, as well as an increase in the incidence of pleural and pericardial effusions requiring drainage, have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/42,45\">",
"     42,45",
"    </a>",
"    ]. Finally, rare but serious cases of sirolimus-related pulmonary toxicity have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Everolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    (Certican) is an analog of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    that was approved for clinical use in the United States for treatment of advanced renal cell carcinoma (2009) and more recently for the prevention of rejection in kidney transplantation (2010). The main difference between sirolimus and everolimus is that the half-life of everolimus (30 hours) is approximately half that of sirolimus (60 hours). In a randomized, double-blind trial of 634 heart transplant recipients, the use of two concentrations of everolimus (1.5 and 3.0",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . All patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and corticosteroids. At six months post-transplantation, significantly fewer patients in the 1.5 mg everolimus group (36 versus 47 percent, p = 0.03) and 3.0 mg everolimus group (27 versus 47 percent, p &lt;0.001) reached the primary efficacy composite endpoint of death, graft loss or retransplantation, loss to follow-up, biopsy-proven moderate to severe acute cellular rejection, or rejection with hemodynamic compromise, compared to the azathioprine group.",
"   </p>",
"   <p>",
"    The difference in efficacy between the groups was almost entirely due to a decreased incidence of acute cellular rejection in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    groups. Additionally, the incidence of allograft vasculopathy as detected by intravascular ultrasound was significantly lower in the everolimus groups compared to the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    group. In this study, everolimus therapy was associated with a significant increase in serum creatinine concentration compared to azathioprine, an effect that was likely due to the potentiation of the nephrotoxic effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    by everolimus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/49\">",
"     49",
"    </a>",
"    ]. The effects of everolimus on rejection rates, allograft vasculopathy, and renal function were sustained at 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multi-center, randomized, open-label non-inferiority study is currently underway, comparing the efficacy and safety of two exposures of concentration-controlled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    (1.5 and 3.0",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    used with reduced dose modified",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (Neoral) versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil used with standard dose modified cyclosporine. The primary objective of this study is to assess if comparable rates of the composite efficacy endpoint of death, graft loss or re-transplantation, loss to follow-up, biopsy-proven moderate to severe acute cellular rejection, or rejection with hemodynamic compromise are achieved in the three cohorts at 12 months post-transplantation. A primary secondary objective of this study will be to demonstrate non-inferior renal function at 12 months in the everolimus treatment arms compared to the MMF arm. Finally, an intravascular ultrasound sub-study will evaluate the incidence of cardiac allograft vasculopathy in the everolimus and MMF groups at 12 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are non-specific anti-inflammatory agents that interrupt multiple steps in immune activation, including antigen presentation, cytokine production, and proliferation of lymphocytes. Although steroids are highly effective for the prevention and treatment of acute rejection, their long-term use is associated with a number of adverse effects, including new onset or worsening diabetes mellitus, hyperlipidemia, hypertension, fluid retention, myopathy, osteoporosis, and a predisposition toward opportunistic infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, while most programs employ corticosteroids as one of the three maintenance immunosuppressive agents, they are used in relatively high doses in the early postoperative period but then tapered to low doses or discontinued altogether after the first 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. Certain low-risk patients may tolerate earlier (within one to two months post-transplantation) steroid withdrawal without long-term adverse consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     TRENDS IN DRUG USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;International trends in the use of maintenance immunosuppressive agents at one year post-transplantation include a steady increase in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    since 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/1\">",
"     1",
"    </a>",
"    ]. Tacrolimus is currently the most widely used calcineurin inhibitor (69 percent of patients) in heart transplantation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil remains the predominant antimetabolite agent (84 percent of patients). The use of the antiproliferative agents",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    has remained low at both one year (11 percent of patients) and five years (23 percent of patients) of follow-up. Finally, 89 percent of patients remained on some amount of glucocorticoid at one year post-transplantation. With respect to drug combinations, use of tacrolimus and MMF with or without steroids was most common (46 percent of patients), followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and MMF with or without steroids (39 percent patients). For additional information, see",
"    <a class=\"external\" href=\"file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\">",
"     file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most programs employ a standard de novo immunosuppressive regimen immediately after transplantation. Once stabilized on a particular regimen, immunosuppressive agents are not routinely altered except in response to significant drug toxicities or post-transplant complications. The most common changes in drug regimens and their rationale are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Refractory or recurrent rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following one or more episodes of acute rejection, many centers will attempt to optimize a patient's baseline immunosuppression. Some programs that routinely utilize",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    as the de-no calcineurin-inhibitor of choice will switch patients to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . Patients previously on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    may be converted to the newer and more effective antimetabolite agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil. Finally, patients on either azathioprine or mycophenolate mofetil may be converted to the proliferation signal inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14441?source=see_link\">",
"     \"Acute cardiac allograft rejection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several renal sparing protocols are employed to slow or reverse the progression of calcineurin inhibitor-mediated renal insufficiency. Strategies include use of the proliferation signal inhibitors in lieu of the antimetabolite agents to allow minimization of the calcineurin-inhibitor dosage or complete withdrawal of the calcineurin-inhibitors in favor of using the combination of a proliferation signal inhibitor and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (CNI-free regimens). Both strategies have resulted in significant improvements in renal function without an increase in the rate of acute rejection or graft dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/57-64\">",
"     57-64",
"    </a>",
"    ]. Additionally, the use of CNI-free regimens may provide additional improvements in renal function compared to low-dose CNI strategies in carefully selected patients who are at low risk of rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Of note, use of a CNI-free regimen as de novo immunosuppression in the early (within 12 weeks) post-operative period or in patients at higher risk for rejection should be done with caution due to the observed increased incidence of biopsy-proven rejection in these settings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/43,67\">",
"     43,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Cardiac allograft vasculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because mTOR also signals smooth muscle cell and endothelial cell proliferation in response to growth factors, the proliferation signal inhibitors have been used to slow allograft vascular disease progression and to reduce the incidence of clinically significant cardiac events when used in a de novo setting after heart transplantation or in patients with established disease on the basis of intravascular ultrasound or coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/44,49,68,69\">",
"     44,49,68,69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=see_link\">",
"     \"Prevention and treatment of cardiac allograft vasculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational data, mostly from the kidney transplant literature, suggest that the proliferation signal inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    may reduce the incidence of post-transplant malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. Limited data also suggest that sirolimus monotherapy may cause regression of certain skin tumors, such as Kaposi sarcoma, in kidney transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/73\">",
"     73",
"    </a>",
"    ]. Postulated mechanisms responsible for this anti-tumor effect include direct antiproliferative actions of these drugs on tumor growth and angiogenesis, as well as facilitation of CNI dose reduction or withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/74\">",
"     74",
"    </a>",
"    ]. Randomized, controlled clinical trials adequately powered within each organ group will be required to determine if the proliferation signal inhibitors are effective for prevention and treatment of post-transplant malignancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain side effects, such as hirsutism or gingival hyperplasia, are unique to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Therefore, individuals who develop severe forms of these complications on cyclosporine may be converted to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . Patients with persistent upper gastrointestinal symptoms on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil despite an initial dose reduction may better tolerate enteric-coated mycophenolate sodium. Severe cases of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -related lower extremity edema and rare but potentially life-threatening episodes of sirolimus-related interstitial pneumonitis will prompt most centers to discontinue the drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians involved in the care of heart transplant recipients should be aware of the potential for drug interactions when other agents are added to or deleted from a patient's medical regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/75\">",
"     75",
"    </a>",
"    ]. A common juncture for such changes is when a transplant recipient requires anti-infective therapy.",
"   </p>",
"   <p>",
"    A list of the most common and clinically important drug interactions is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef78597 \" href=\"UTD.htm?39/60/40908\">",
"     table 2",
"    </a>",
"    ). Specific interactions of antirejection agents with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"   </p>",
"   <p>",
"    Drug interactions involving immunosuppressive agents are numerous and medication regimens for transplant recipients are complex. While most drug interactions are not clinically significant and few combinations are absolutely contraindicated, many can create serious consequences in the absence of appropriate monitoring and dose adjustments. Preventable consequences can include organ rejection or acute kidney injury from supratherapeutic levels of calcineurin inhibitors. An evaluation by a clinical pharmacist with transplant expertise may be valuable in some instances.",
"   </p>",
"   <p>",
"    One combination involving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    should be",
"    <strong>",
"     avoided",
"    </strong>",
"    . Allopurinol inhibits the activity of xanthine oxidase, which is involved in the metabolism of azathioprine, resulting in high levels of the active metabolite 6-mercaptopurine and possible severe bone marrow suppression.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    is an alternative to azathioprine in patients who require allopurinol therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Pharmacokinetic drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacokinetic drug interactions occur when a drug changes the immunosuppressive drug blood concentration profile, by interfering with the absorption, distribution, metabolism, or elimination of the immunosuppressive agent. Most clinically important pharmacokinetic drug interactions occur due to altered drug metabolism. The calcineurin inhibitors and proliferation signal inhibitors are extensively metabolized by the cytochrome P-450 3A4 enzyme pathway in the liver so their blood levels are affected by drugs that induce or inhibit this pathway.",
"   </p>",
"   <p>",
"    Drugs that",
"    <strong>",
"     induce",
"    </strong>",
"    the P-450 3A4 pathway result in enhanced metabolism of the calcineurin inhibitors and proliferation signal inhibitors, thus",
"    <strong>",
"     lowering",
"    </strong>",
"    their blood levels and clinical effectiveness. Strong inducers of cytochrome P-450 3A4 inducers include certain antiepileptic drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ), the antitubercular agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , certain antiretroviral agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ), and the herbal agent St. John's wort.",
"   </p>",
"   <p>",
"    Conversely, drugs that",
"    <strong>",
"     inhibit",
"    </strong>",
"    the cytochrome P-450 3A4 enzyme pathway result in decreased metabolism of the calcineurin inhibitors and proliferation signal inhibitors, thereby",
"    <strong>",
"     increasing",
"    </strong>",
"    their blood levels and potentiating their toxicities. Many drugs inhibit cytochrome P-450 3A4 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/1/18458/abstract/76\">",
"     76",
"    </a>",
"    ]. Common inhibitors include the macrolide antibiotics, nondihydropyridine calcium channel blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , and several antiretroviral drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Pharmacodynamic drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacodynamic drug interactions occur when a drug modulates an immunosuppressive agent's effect at a given blood concentration, either increasing or diminishing the immunosuppressive drug's therapeutic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    toxic effects. For example, concurrent use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    can potentiate the myelosuppressive effects of the antimetabolite agents and proliferation signal inhibitors. Another example is additive nephrotoxicity is observed when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , aminoglycosides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    , or nonsteroidal anti-inflammatory agents are used with the calcineurin inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/36/26179?source=see_link\">",
"       \"Patient information: Heart transplantation (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction and maintenance immunosuppressive regimens after heart transplantation vary according to transplant center experience and recipient characteristics (renal function, baseline risk of rejection, and individual drug tolerability). However, most regimens adhere to the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of universal induction therapy remains controversial. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Induction therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Induction therapy may be of benefit in the subset of patients with the highest risk of acute rejection (pre-sensitized patients, young patients, female patients, and African American patients) and in patients with impaired renal function to allow delayed initiation of calcineurin-inhibitors post-transplantation.",
"     </li>",
"     <li>",
"      The optimal induction agent has not been clearly defined, but the anti-thymocyte polyclonal antibodies and the IL-2 receptor antagonists have largely replaced the older agent OKT3 due to their improved safety and tolerability profile.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most modern immunosuppressive regimens consist of a two or three-drug regimen, including a calcineurin-inhibitor (either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ), an antimetabolite agent (typically",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil), and tapering doses of corticosteroids over the first year.",
"     </li>",
"     <li>",
"      Although",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      are both highly effective agents, evidence from clinical trials suggests that tacrolimus-based immunosuppression may offer an advantage over cyclosporine-based regimens with respect to decreased rates of acute rejection and an overall more favorable metabolic derangement profile (decreased incidence of hypertension and hyperlipidemia but higher incidence of post-transplant diabetes).",
"     </li>",
"     <li>",
"      The proliferation signal inhibitors",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      are typically used in patients with cardiac allograft vasculopathy or renal insufficiency. Due to their inhibitory effects on smooth muscle proliferation and absence of intrinsic nephrotoxicity, they have been useful for slowing disease progression in these settings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The high incidence of drug-related adverse effects, including lower extremity edema, oral ulcerations, and poor wound healing, may limit generalized use of these agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The calcineurin inhibitors and proliferation signal inhibitors are heavily metabolized by the cytochrome P450 3A4 pathway and therefore are susceptible to numerous drug interactions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Clinicians managing heart transplant patients should become familiar with the common agents that can increase immunosuppressive drug levels (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ), decrease drug levels (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      , St. John's wort), or potentiate the toxic properties of immunosuppressive agents (eg, nephrotoxicity associated with non-steroidal anti-inflammatory agents and aminoglycoside antibiotics). When these drugs are added to or deleted from a patient's baseline regimen, immunosuppressive drug levels and renal function should be carefully monitored.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/1\">",
"      Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report--2010. J Heart Lung Transplant 2010; 29:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/2\">",
"      Rosenberg PB, Vriesendorp AE, Drazner MH, et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 2005; 24:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/3\">",
"      Yamani MH, Taylor DO, Czerr J, et al. Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study. Clin Transplant 2008; 22:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/4\">",
"      Cantarovich M, Giannetti N, Barkun J, Cecere R. Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction. Transplantation 2004; 78:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/5\">",
"      Adamson R, Obispo E, Dychter S, et al. Long-term outcome with the use of OKT3 induction therapy in heart transplant patients: a single-center experience. Transplant Proc 1998; 30:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/6\">",
"      Johnson MR, Mullen GM, O'Sullivan EJ, et al. Risk/benefit ratio of perioperative OKT3 in cardiac transplantation. Am J Cardiol 1994; 74:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/7\">",
"      Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/8\">",
"      Opelz G, D&ouml;hler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/9\">",
"      Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 2000; 342:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/10\">",
"      Prieto M, Lake KD, Pritzker MR, et al. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients. J Heart Lung Transplant 1991; 10:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/11\">",
"      Rinaldi M, Pellegrini C, D'Armini AM, et al. Neoplastic disease after heart transplantation: single center experience. Eur J Cardiothorac Surg 2001; 19:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/12\">",
"      Higgins R, Kirklin JK, Brown RN, et al. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy? J Heart Lung Transplant 2005; 24:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/13\">",
"      Segovia J, Rodr&iacute;guez-Lambert JL, Crespo-Leiro MG, et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation 2006; 81:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/14\">",
"      Mattei MF, Redonnet M, Gandjbakhch I, et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant 2007; 26:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/15\">",
"      Mehra MR, Zucker MJ, Wagoner L, et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 2005; 24:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/16\">",
"      Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005; 352:2705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/17\">",
"      Hardinger KL, Rhee S, Buchanan P, et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation 2008; 86:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/18\">",
"      Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/19\">",
"      El-Hamamsy I, Stevens LM, Carrier M, et al. Incidence and prognosis of cancer following heart transplantation using RATG induction therapy. Transpl Int 2005; 18:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/20\">",
"      Carrier M, Leblanc MH, Perrault LP, et al. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. J Heart Lung Transplant 2007; 26:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/21\">",
"      Caillat-Zucman S, Blumenfeld N, Legendre C, et al. The OKT3 immunosuppressive effect. In situ antigenic modulation of human graft-infiltrating T cells. Transplantation 1990; 49:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/22\">",
"      Norman DJ. Mechanisms of action and overview of OKT3. Ther Drug Monit 1995; 17:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/23\">",
"      Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/24\">",
"      Jensen PB, Birkeland SA, Rohrp N, et al. Development of anti-OKT3 antibodies after OKT3 treatment. Scand J Urol Nephrol 1996; 30:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/25\">",
"      Hammond EH, Wittwer CT, Greenwood J, et al. Relationship of OKT3 sensitization and vascular rejection in cardiac transplant patients receiving OKT3 rejection prophylaxis. Transplantation 1990; 50:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/26\">",
"      Bloom DD, Hu H, Fechner JH, Knechtle SJ. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 2006; 81:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/27\">",
"      Morris PJ, Russell NK. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 2006; 81:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/28\">",
"      Teuteberg JJ, Shullo MA, Zomak R, et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant 2010; 10:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/29\">",
"      Grimm M, Rinaldi M, Yonan NA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients--a large European trial. Am J Transplant 2006; 6:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/30\">",
"      Groetzner J, Meiser BM, Schirmer J, et al. Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up? Transplant Proc 2001; 33:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/31\">",
"      Meiser BM, Uberfuhr P, Fuchs A, et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. J Heart Lung Transplant 1998; 17:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/32\">",
"      Rinaldi M, Pellegrini C, Martinelli L, et al. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study. J Heart Lung Transplant 1997; 16:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/33\">",
"      Reichart B, Meiser B, Vigan&ograve; M, et al. European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results--European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant 1998; 17:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/34\">",
"      Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/35\">",
"      Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/36\">",
"      Kobashigawa JA, Patel J, Furukawa H, et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006; 25:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/37\">",
"      Eisen HJ, Hobbs RE, Davis SF, et al. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine--results at 24 months after transplantation. Transplantation 2001; 71:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/38\">",
"      Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66:507.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm072438.htm (Accessed on June 12, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/40\">",
"      Kobashigawa JA, Renlund DG, Gerosa G, et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant 2006; 25:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/41\">",
"      Lehmkuhl H, Hummel M, Kobashigawa J, et al. Enteric-coated mycophenolate-sodium in heart transplantation: efficacy, safety, and pharmacokinetic compared with mycophenolate mofetil. Transplant Proc 2008; 40:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/42\">",
"      Kuppahally S, Al-Khaldi A, Weisshaar D, et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006; 6:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/43\">",
"      Gonz&aacute;lez-V&iacute;lchez F, de Prada JA, Exposito V, et al. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure. J Heart Lung Transplant 2008; 27:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/44\">",
"      Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110:2694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/45\">",
"      Zakliczynski M, Nozynski J, Kocher A, et al. Surgical wound-healing complications in heart transplant recipients treated with rapamycin. Wound Repair Regen 2007; 15:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/46\">",
"      Garc&iacute;a-Luque A, Cordero E, Torell&oacute; J, et al. Sirolimus-associated pneumonitis in heart transplant recipients. Ann Pharmacother 2008; 42:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/47\">",
"      Khalife WI, Kogoj P, Kar B. Sirolimus-induced alveolar hemorrhage. J Heart Lung Transplant 2007; 26:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/48\">",
"      Delgado JF, Torres J, Jos&eacute; Ruiz-Cano M, et al. Sirolimus-associated interstitial pneumonitis in 3 heart transplant recipients. J Heart Lung Transplant 2006; 25:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/49\">",
"      Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/50\">",
"      Vigan&ograve; M, Tuzcu M, Benza R, et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant 2007; 26:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/51\">",
"      Miller LW, Wolford T, McBride LR, et al. Successful withdrawal of corticosteroids in heart transplantation. J Heart Lung Transplant 1992; 11:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/52\">",
"      Olivari MT, Jessen ME, Baldwin BJ, et al. Triple-drug immunosuppression with steroid discontinuation by six months after heart transplantation. J Heart Lung Transplant 1995; 14:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/53\">",
"      Kobashigawa JA, Stevenson LW, Brownfield ED, et al. Initial success of steroid weaning late after heart transplantation. J Heart Lung Transplant 1992; 11:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/54\">",
"      Teuteberg JJ, Shullo M, Zomak R, et al. Aggressive steroid weaning after cardiac transplantation is possible without the additional risk of significant rejection. Clin Transplant 2008; 22:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/55\">",
"      Taylor DO, Bristow MR, O'Connell JB, et al. Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy. J Heart Lung Transplant 1996; 15:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/56\">",
"      Renlund DG, O'Connell JB, Gilbert EM, et al. Feasibility of discontinuation of corticosteroid maintenance therapy in heart transplantation. J Heart Transplant 1987; 6:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/57\">",
"      Gustafsson F, Ross HJ, Delgado MS, et al. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction. J Heart Lung Transplant 2007; 26:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/58\">",
"      Raichlin E, Khalpey Z, Kremers W, et al. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. Transplantation 2007; 84:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/59\">",
"      Rothenburger M, Teerling E, Bruch C, et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant 2007; 26:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/60\">",
"      Bestetti R, Theodoropoulos TA, Burdmann EA, et al. Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up. Transplantation 2006; 81:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/61\">",
"      Fernandez-Valls M, Gonzalez-Vilchez F, de Prada JA, et al. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center. Transplant Proc 2005; 37:4021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/62\">",
"      Kushwaha SS, Khalpey Z, Frantz RP, et al. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 2005; 24:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/63\">",
"      Hunt J, Lerman M, Magee MJ, et al. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. J Heart Lung Transplant 2005; 24:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/64\">",
"      Groetzner J, Kaczmarek I, Landwehr P, et al. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients. Eur J Cardiothorac Surg 2004; 25:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/65\">",
"      Gleissner CA, Doesch A, Ehlermann P, et al. Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy. Am J Transplant 2006; 6:2750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/66\">",
"      Potter BJ, Giannetti N, Edwardes MD, et al. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients. Clin Transplant 2007; 21:305.",
"     </a>",
"    </li>",
"    <li>",
"     Roche Laboratories Inc. Higher than expected incidence of acute rejection in cardiac transplant patients switched from calcineurin inhibitors in combination with CellCept (mycophenolate mofetil) to Rapamune (sirolimus) in combination with CellCept at 12 weeks post heart transplantation. 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/68\">",
"      Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/69\">",
"      Raichlin E, Bae JH, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 2007; 116:2726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/70\">",
"      Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/71\">",
"      Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/72\">",
"      Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/73\">",
"      Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/74\">",
"      Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/1/18458/abstract/75\">",
"      Page RL 2nd, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. Circulation 2005; 111:230.",
"     </a>",
"    </li>",
"    <li>",
"     Oesterheld JR. 3A4 (chap 6) in Clinical manual of drug interaction principles for medical practice. Wynn, GH, Oesterheld, JR, Cozza, KL, Armstrong, SC. American psychiatric publishing, inc. (2009). Washington DC.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3530 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-CDD449C725-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_1_18458=[""].join("\n");
var outline_f18_1_18458=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDUCTION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Interleukin-2 receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Polyclonal anti-thymocyte antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Muromonab-CD3 (OKT3)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MAINTENANCE IMMUNOSUPPRESSIVE REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Calcineurin-inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Dosing and therapeutic drug monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Major toxicities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Dosing and therapeutic drug monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Major toxicities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ANTIMETABOLITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Dosing and therapeutic drug monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Major toxicities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Mycophenolate sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROLIFERATION SIGNAL INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Sirolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Dosing and therapeutic drug monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Major toxicities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Everolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      TRENDS IN DRUG USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Refractory or recurrent rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Pharmacokinetic drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Pharmacodynamic drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3530\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3530|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/55/23421\" title=\"table 1\">",
"      Immunosuppressive agents used in heart transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/60/40908\" title=\"table 2\">",
"      Important immunosuppresive drug interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14441?source=related_link\">",
"      Acute cardiac allograft rejection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32649?source=related_link\">",
"      Induction immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/36/26179?source=related_link\">",
"      Patient information: Heart transplantation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=related_link\">",
"      Prevention and treatment of cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_1_18459="Possible causes of hypotension in a potential organ donor";
var content_f18_1_18459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Possible causes of hypotension in a potential organ donor",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Hypovolemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Polyuria due to diabetes insipidus or osmotic diuresis due to hyperglycemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fluid restriction strategies for cerebral protection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inadequate fluid restriction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bleeding",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Distributive shock",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Systemic inflammatory response syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Post brain stem death vasodilatation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Cardiogenic shock",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Myocardial trauma: blunt contusion, penetrating injury",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Electrolyte abnormality",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypothermia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Endocrine and metabolic abnormalities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anterior pituitary dysfunction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Adrenal insufficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diabetes insipidus",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_1_18459=[""].join("\n");
var outline_f18_1_18459=null;
var title_f18_1_18460="Recommended antiepileptic drugs";
var content_f18_1_18460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Epileptic syndromes and recommended antiepileptic drugs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antiepileptic drug",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Localization-related (partial, focal)",
"       </td>",
"       <td>",
"        1 - CBZ, PB, VPA, TPM, PHT, LTG, OXC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 - GBP, PRM, CRZ, LEV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Generalized epilepsies&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\" colspan=\"1\" rowspan=\"2\">",
"        Absence seizures",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 - ESM, VPA, LTG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        2 - CNZ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\" colspan=\"1\" rowspan=\"2\">",
"        Generalized tonic-clonic",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 - CBZ, VPA, PHT, PB, TPM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        2 - LTG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\" colspan=\"1\" rowspan=\"2\">",
"        Juvenile myoclonic epilepsy",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 - VPA, LMG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        2 - PRM, CNZ, TPM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\" colspan=\"1\" rowspan=\"2\">",
"        Myoclonic absence",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 - VPA, ESM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        2 - LTG, CNZ, TPM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Infantile spasms",
"       </td>",
"       <td>",
"        1 - ACTH, prednisone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 - VPA (?), CNZ (?), TPM (?)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Lennox-Gastaut syndrome",
"       </td>",
"       <td>",
"        1 - VPA, LTG, CNZ, CRZ, CBZ, TPM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 - ESM (drop attacks), FBM",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CBZ: carbamazepine; CRZ: clorazepate; CNZ: clonazepam; ESM: ethosuximide; FBM: felbamate; GBP: gabapentin; LEV: levetiracetam; LTG: lamotrigine; OXC: oxcarbazepine; PHT: phenytoin; PB: phenobarbital; PRM: primidone; TPM: topiramate; TGB: tiagabine; VPA: valproic acid (divalproex sodium).",
"     <br>",
"      1: first line drugs.",
"      <br>",
"       2: second line drugs.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Tharp, BR, Epilepsy in Infants and Children. In: Conn's Current Therapy, Rakel, RE (Ed), W.B. Saunders 1998; p.883.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_1_18460=[""].join("\n");
var outline_f18_1_18460=null;
var title_f18_1_18461="Age-specific diagnostic priorities for children with ALF";
var content_f18_1_18461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Age-specific diagnostic priorities for children with acute liver failure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        &lt;3 months of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpes blood PCR (or other testing: HSV IgM, viral culture of blood or CSF, CSF PCR)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enterovirus blood PCR (or other testing)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactate, pyruvate (mitochondrial screen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma acylcarnitine profile (fatty acid oxidation defects)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ferritin (screen for gestational alloimmune liver disease [neonatal hemachromatosis])",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum amino acid profile (urea cycle and metabolic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echocardiogram: Cardiac dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal ultrasound with Doppler (vascular and anatomic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Confirm newborn screening results (galactosemia and tyrosinemia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Confirm maternal hepatitis B serology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        3 months to 4 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HBsAg, HAV IgM, EBV VCA IgM or EBV PCR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactate, pyruvate (mitochondrial screen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune markers: ANA, ASMA, ALKM, IgG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug history, acetaminophen level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma acylcarnitine profile (fatty acid oxidation defects)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum amino acids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal ultrasound with Doppler (vascular and anatomic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        5 years to 18 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HBsAg, HAV IgM, EBV (EBV VCA IgM or PCR)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune markers: ANA, ASMA, ALKM, IgG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceruloplasmin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug history, acetaminophen level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactate, pyruvate (screen for mitochondrial disorders)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma acylcarnitine profile (Fatty acid oxidation defects)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum amino acids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal ultrasound with Doppler (vascular and anatomic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Additional diagnostic screening tests to consider, directed by history and clinical course",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Infectious causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Blood culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Viral PCR in blood for adenovirus, enterovirus, EBV, HHV-6, parvovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nasal wash for influenza (infections)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hepatitis E antibody",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serologic tests for celiac disease&nbsp;(eg, tissue transglutaminase)&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soluble IL2R, ferritin in older patients, triglycerides (hemophagocytic lymphohistiocytosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echocardiogram (cardiac)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MRI for tissue iron (gestational alloimmune liver disease [neonatal hemochromatosis])",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine succinyl acetone (tyrosinemia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine orotic acid (urea cycle defects)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine organic acids (metabolic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver copper, Wilson gene mutation analysis (Wilson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver biopsy for histology, culture, electron microscopy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PCR: polymerase chain reaction; HSV: herpes simplex virus; IgM: immunoglobulin M; CSF: cerebrospinal fluid; HBsAg: hepatitis B s antigen; HAV: hepatitis A virus; EBV: Epstein-Barr virus; VCA: viral capsid antigen; ANA: anti-nuclear antibodies; ASMA: anti-smooth muscle antibodies; ALKM: anti-liver-kidney microsomal antibodies; HHV-6: human herpes virus 6; IL2R: interleukin 2 receptor. MRI: magnetic resonance imaging.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Squires RH, Alonso EM. Acute liver failure in children. In: Liver Disease in Children, 4th ed, Suchy FJ, Sokol RJ, Balistreri WF (Eds), Cambridge University Press, New York 2012. Copyright &copy; 2012 Cambridge University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_1_18461=[""].join("\n");
var outline_f18_1_18461=null;
var title_f18_1_18462="Contents: Ear, nose, and throat";
var content_f18_1_18462=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Ear, nose, and throat",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Ear, nose, and throat",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Ear wax impaction",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/46/32482\">",
"           Patient information: Ear wax impaction (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Eustachian tube problems",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/45/25298\">",
"           Patient information: Eustachian tube problems (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hearing loss",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/26/33186\">",
"           Patient information: Age-related hearing loss (presbycusis) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/46/32482\">",
"           Patient information: Ear wax impaction (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/19/34097\">",
"           Patient information: Screening for hearing loss in newborns (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/20/44353\">",
"           Patient information: Vestibular schwannoma (acoustic neuroma) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Labyrinthitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/10/26785\">",
"           Patient information: Labyrinthitis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Laryngitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/29/26066\">",
"           Patient information: Laryngitis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Meniere disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/10/40097\">",
"           Patient information: Meniere disease (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nose and sinuses",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/13/37073\">",
"           Patient information: Acute sinusitis (sinus infection) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/8/41092\">",
"           Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/58/42915\">",
"           Patient information: Chronic rhinosinusitis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/37/14930\">",
"           Patient information: Chronic sinusitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/12/11457\">",
"           Patient information: Deviated septum (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/18/29985\">",
"           Patient information: Nasal polyps (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/15/24818\">",
"           Patient information: Nonallergic rhinitis (runny or stuffy nose) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/18/16674\">",
"           Patient information: Rinsing out your nose with salt water (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/38/37474\">",
"           Patient information: Seasonal allergies in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/10/13475\">",
"           Patient information: Seasonal allergies in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/53/17234\">",
"           Patient information: Sinusitis in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/40/5764\">",
"           Patient information: Trigger avoidance in allergic rhinitis (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nosebleed",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/50/1826\">",
"           Patient information: Nosebleeds (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/10/19617\">",
"           Patient information: Nosebleeds (epistaxis) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Objects in ear",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/57/10130\">",
"           Patient information: Removing objects stuck in the ear (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Objects in nose",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/38/1634\">",
"           Patient information: Removing objects stuck up the nose (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ruptured eardrum",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/45/36561\">",
"           Patient information: Ruptured eardrum (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Swallowed objects",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/24/14722\">",
"           Patient information: Swallowed objects (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tinnitus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/42/18082\">",
"           Patient information: Tinnitus (ringing in the ears) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/26/43425\">",
"           Patient information: Tinnitus (ringing in the ears) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-EA6F480CB6-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f18_1_18462=[""].join("\n");
var outline_f18_1_18462=null;
var title_f18_1_18463="Contents: Fungal infections";
var content_f18_1_18463=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Fungal infections",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Fungal infections",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Antifungal drugs",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/5/38998\">",
"           Amphotericin B nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/21/29018\">",
"           Antifungal susceptibility testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/41/15001\">",
"           Pharmacology of amphotericin B",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/4/36938\">",
"           Pharmacology of azoles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/7/9338\">",
"           Pharmacology of echinocandins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/11/43190\">",
"           Pharmacology of flucytosine (5-FC)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Aspergillus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/48/33545\">",
"           Allergic bronchopulmonary aspergillosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/56/22408\">",
"           Clinical manifestations and diagnosis of chronic pulmonary aspergillosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/52/3913\">",
"           Diagnosis of invasive aspergillosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/51/34616\">",
"           Epidemiology and clinical manifestations of invasive aspergillosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/18/28970\">",
"           Treatment and prevention of invasive aspergillosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/50/31529\">",
"           Treatment of chronic pulmonary aspergillosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Blastomycosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/57/35736\">",
"           Clinical manifestations and diagnosis of blastomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/4/79\">",
"           Mycology, pathogenesis, and epidemiology of blastomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/13/29912\">",
"           Treatment of blastomycosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Candida",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/19/37176\">",
"           Biology of Candida infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/39/40566\">",
"           Candida endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/40/18055\">",
"           Candida infections of the abdomen and thorax",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/49/15128\">",
"           Candida infections of the bladder and kidneys",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/40/39559\">",
"           Candida infections of the central nervous system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/25/11671\">",
"           Candida osteoarticular infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/6/36966\">",
"           Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/17/29972\">",
"           Clinical manifestations of oropharyngeal and esophageal candidiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/48/37638\">",
"           Epidemiology and pathogenesis of candidemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/33/13849\">",
"           Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/27/8631\">",
"           Fungal peritonitis in continuous peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/53/10071\">",
"           Hepatosplenic candidiasis (chronic disseminated candidiasis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/5/42071\">",
"           Overview of Candida infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/13/29914\">",
"           Treatment of candidemia and invasive candidiasis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/12/39112\">",
"           Treatment of endogenous endophthalmitis due to Candida species",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/16/36102\">",
"           Treatment of exogenous endophthalmitis due to Candida species",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/19/20793\">",
"           Treatment of oropharyngeal and esophageal candidiasis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Coccidioides",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/55/17271\">",
"           Coccidioidal meningitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/21/21848\">",
"           Coccidioidomycosis in compromised hosts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/27/13751\">",
"           Laboratory diagnosis of coccidioidomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/51/39734\">",
"           Management of pulmonary sequelae and complications of coccidioidomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/11/26807\">",
"           Manifestations and treatment of extrapulmonary coccidioidomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/26/425\">",
"           Primary coccidioidal infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cryptococcus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/42/38568\">",
"           Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/2/19494\">",
"           Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/8/13449\">",
"           Cryptococcal infection outside the central nervous system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/61/40919\">",
"           Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/24/37254\">",
"           Microbiology and epidemiology of cryptococcal infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/54/15210\">",
"           Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/23/23929\">",
"           Treatment of cryptococcal meningoencephalitis in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cutaneous infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/59/30648\">",
"           Candidal intertrigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/58/7082\">",
"           Dermatophyte (tinea) infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/15/3320\">",
"           Tinea versicolor",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/49/15128\">",
"           Candida infections of the bladder and kidneys",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/36/8775\">",
"           Fungal rhinosinusitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/19/18746\">",
"           Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/55/19321\">",
"           Outbreak of fungal central nervous system and osteoarticular infections in the United States: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Histoplasmosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/6/9321\">",
"           Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/23/21881\">",
"           Diagnosis and treatment of pulmonary histoplasmosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/24/42376\">",
"           Pathogenesis and clinical features of pulmonary histoplasmosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/6/43112\">",
"           Pathogenesis and clinical manifestations of disseminated histoplasmosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous fungi",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/55/43894\">",
"           Central nervous system infections due to dematiaceous fungi (cerebral phaeohyphomycosis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/29/10712\">",
"           Clinical manifestations and diagnosis of Fusarium infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/35/15928\">",
"           Diagnosis and treatment of Penicillium marneffei infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/25/36249\">",
"           Diagnosis and treatment of Scedosporium infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/33/33302\">",
"           Epidemiology and clinical manifestations of Penicillium marneffei infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/42/41640\">",
"           Epidemiology and clinical manifestations of Scedosporium infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/61/31704\">",
"           Eumycetoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/47/1785\">",
"           Infections due to Trichosporon species and Blastoschizomyces capitatus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/56/6021\">",
"           Malassezia infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/18/6439\">",
"           Mycology, pathogenesis, and epidemiology of Fusarium infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/42/3753\">",
"           Treatment and prevention of Fusarium infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/55/2937\">",
"           Treatment of endophthalmitis due to molds",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mucormycosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/46/6890\">",
"           Mucormycosis (zygomycosis)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Paracoccidioidomycosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/51/40756\">",
"           Clinical manifestations and diagnosis of acute/subacute paracoccidioidomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/4/36935\">",
"           Clinical manifestations and diagnosis of chronic paracoccidioidomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/19/41268\">",
"           Mycology and epidemiology of paracoccidioidomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/37/30295\">",
"           Treatment of paracoccidioidomycosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sporotrichosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/60/8134\">",
"           Basic biology and epidemiology of sporotrichosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/11/12469\">",
"           Clinical features and diagnosis of sporotrichosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/0/34822\">",
"           Treatment of sporotrichosis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-91FCFAEF06-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f18_1_18463=[""].join("\n");
var outline_f18_1_18463=null;
